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Abstract 
 
This study investigated the effects of the ketone body β-hydroxybutyrate (βHB) on glucose 
and fat metabolism in skeletal muscle cells. To accomplish this, L6 muscle cells were incubated 
with various βHB concentrations (0.5, 1.0, 1.5, 20, and 2.5 mM) for 1, 3, and 5 days. Here, we 
report that βHB significantly increased glucose uptake and its metabolism in L6 muscle cells. Time 
course analysis revealed that as early as 1 day of exposure to 1mM βHB significantly enhanced 
basal and insulin-stimulated glucose uptake (1.6-fold), glycogen synthesis (1.3-fold), glucose 
oxidation (1.5-fold), and lactate production (1.3-fold) in skeletal muscle cells. Even though 
carnitine palmitoyl transferase 1 (CPT1) content and AMP-activated protein kinase (AMPK) 
phosphorylation significantly increased, no alteration was found in palmitate oxidation with βHB 
treatment. Surprisingly, protein kinase B (AKT) phosphorylation was significantly reduced in 
muscle cells exposed to βHB. In summary, βHB increased AMPK phosphorylation and enhanced 
glucose uptake without altering fatty acid oxidation in skeletal muscle cells.   
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Introduction   
 
Ketogenic diets (KDs) are characterized by high and low contents of fat and carbohydrates, 
respectively1.  These diets have been known for their therapeutic value in the treatment of 
neurological disorders such as epilepsy2. In recent years, the popularity of KDs has increased due 
to the fact that they can also be beneficial in the treatment of metabolic diseases primarily through 
improvements in whole-body glucose control2. Although KDs have been shown to have broad 
therapeutic potential, patient compliance can be challenging2,3. This is because along with severe 
dietary restriction and unpalatability of meals associated with KDs, those who are on a KD deal 
with possible hypoglycemic episodes and intolerance to high fat ingestion3,4. In this context, it has 
been suggested that oral supplementation of ketones may mimic a metabolic state of ketosis 
without any of the shortcomings of a typical KD, therefore serving as a practical alternative3,5. β-
Hydroxybutyrate (βHB), acetoacetate, and acetone are the ketones produced by the body. 
However, βHB considered the most functionally relevant because of its signaling capabilities and 
the fact that it is less likely to undergo degradation and be eliminated relative to than acetoacetate 
and acetone6,7.  
Therefore, chronic supplementation of βHB has been suggested as an alternative approach 
to create ketogenic conditions without having to adhere to a typical KD. This has been tested both 
in rodent and human models8. Initial studies established that a state of ketosis can be achieved and 
maintained in humans and rodents with various types of ketone/βHB supplements without the need 
for dietary changes5,9. Significant metabolic effects of βHB supplementation were demonstrated 
by a study in which βHB salts were administered orally to rats5. The rats experienced an improved 
plasma lipid profile as well as an overall decrease in adipocyte volume5. Interestingly, high-fat-
fed mice receiving a βHB-ester supplement displayed significant weight loss and an increase in 
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energy expenditure compared to high-fat and calorie-restricted mice10. In humans, 
supplementation of βHB salts resulted an overall increase in fat oxidation and a reduction in 
respiratory exchange ratio (RER), mimicking what is observed in individuals on a KD11. 
Even though several studies report that βHB supplementation can lead to alterations in 
substrate utilization and affect exercise performance, the molecular mechanisms responsible for 
the results described above remains unknown, although some hypotheses have been proposed. 
Once taken up by peripheral tissues, βHB is thought to affect cellular metabolism in two ways: a) 
by inhibiting class 1 histone deacetylases (HDACs), which regulate gene expression12,13, and b) 
through post translational protein modifications including acetylation, succinylation, and β-
Hydroxybutyrylation1,12. One of the most important peripheral tissues that utilize βHB is skeletal 
muscle, which accounts for up to ~40% of body weight in men and ~30% in women. Additionally, 
skeletal muscles are the primary site of insulin-stimulated glucose uptake and play a major role in 
the regulation of glucose and fat homeostasis in the body14,15. Therefore, any potential effect of 
βHB on muscle could be of great physiological and therapeutic relevance and worthy of further 
investigation.  
In this context, the research described in this thesis was designed to investigate the effects 
of βHB on skeletal muscle metabolism. To accomplish that, an in vitro model using L6 rat skeletal 
muscle myoblast cells were used. Using L6 myoblasts allowed for direct assessment of βHB on 
skeletal muscle without potential confounding systemic influences on skeletal muscle metabolism. 
Alterations to important components of glucose and fat metabolism specifically, were analyzed 
using various functional assays including: glucose uptake, glucose oxidation, glycogen synthesis, 
lactate production, and palmitate oxidation in myoblasts. Western blot analysis was used to assess 
alterations in signaling pathways related to glucose and fat metabolism. These included 
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phosphorylation protein kinase B (AKT), AMP-activated protein kinase (AMPK), glycogen 
synthase (GS), and glycogen synthase kinase 3 (GSK3), as well as content of carnitine palmitoyl 
transferase 1B (CPT1B). Using these data, the role of βHB in the regulation of skeletal muscle cell 
metabolism was evaluated.  
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Literature Review 
Metabolism of ketones  
A typical KD consists of a 4:1 ratio of grams of fat to carbohydrates, while reducing total 
carbohydrate intake to less than 50 grams per day. More restricted KDs can reduce carbohydrate 
consumption to as low as 20 grams per day. Generally, KDs suggest obtaining 70-80% of total 
daily calories from fat, 5-10% from carbohydrates, and 10-20% from protein. The amount of 
protein is kept moderate as too little protein intake can lead to muscle loss and decreased satiety. 
Too much protein intake can prevent ketosis as gluconeogenic amino acids can be converted into 
glucose16,17,18,4,19.  
KDs induce metabolic changes in the organism by lowering blood glucose levels as a result 
of reduced carbohydrate intake20,21. This leads to a reduction in insulin release and increased 
glucagon secretion from the pancreatic β and α-cells, respectively21,6. The low insulin: glucagon 
ratio increases hepatic gluconeogenesis to provide glucose to tissues such as brain and red blood 
cells that rely on glucose for energy production20,21,6. Low levels of circulating insulin enhances 
lipolysis and allows the body to mobilize fat stores within adipose tissue6,22. Stored triglycerides 
within adipocytes are actively hydrolyzed into non-esterified fatty acids (NEFAs) and glycerol, 
which are then released into the bloodstream22,23. Glycerol is taken up by the liver where it is used 
as a substrate for gluconeogenesis22,23. With the exception of erythrocytes and the brain, peripheral 
tissues uptake NEFAs where they enter mitochondria, peroxisomes, or endoplasmic reticulum to 
undergo oxidation6,22,23. An increase in hepatic uptake of NEFAs leads to high rates of β-oxidation 
resulting in surplus acetyl-CoA production, which is directed towards ketogenesis24. The ketone 
bodies, namely β-hydroxybutyrate (βHB), acetoacetate (AcAc), and acetone are formed (Fig. 
1)6,25. In addition to increased acetyl-CoA produced from β-oxidation, the formation of ketone 
bodies is exacerbated by the reduction in hepatic mitochondrial oxaloacetate. This component of 
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the TCA cycle is diverted to gluconeogenesis, which reduces its availability for condensation with 
acetyl-CoA and formation of citrate21.  As a consequence, more acetyl-CoA is diverted toward the 
formation of ketone bodies6,25.  
 Acetoacetate (AcAc) is initially formed by the condensation of two acetyl-CoA molecules 
and a small fraction of AcAc enters the circulation to be taken up by peripheral tissues for energy 
production26-29 (Fig. 1-2). Another fraction spontaneously decarboxylates into acetone, which is 
volatile and can be eliminated through breathing. In fact, it is acetone that confers the “fruity odor” 
to the breath of individuals in ketosis27,28. Most of the AcAc produced however, is reduced to βHB, 
which is the primary circulating ketone29. Under conditions of low carbohydrate intake, AcAc and 
primarily βHB play a key role in sparing glucose for use by the brain and erythrocytes, which 
cannot utilize fatty acids for energy26. In the case of the brain, βHB can function as an alternative 
energy source accounting for up to two thirds of its energy needs while on a KD or during periods 
of prolonged fasting or starvation29.  
 Ketone bodies are present in small amounts in the circulation of healthy individuals with 
basal serum levels of βHB typically in the low μM range (25-150μM)  rising up to a few hundred 
μM (150-900μM) with 12-16 hours of fasting2,30. Significant elevations in circulating ketone body 
levels are seen in specific physiological states29. For example, two days of fasting can bring serum 
levels of βHB up to 1-2mM, where prolonged starvation can result in βHB levels reaching 6-
8mM2,30. compared to basal levels. Variations in βHB levels are thought to be caused by 
differences in hepatic glycogen stores, basal metabolic rate, and mobilization of amino acids from 
muscle protein break down29.  Similar levels can be attained with 90 minutes of intense exercise 
or by adopting a KD2,30. Infants can achieve serum βHB levels of 0.5-2.5mM while on diet typical 
for a child of that age. Within 8-10 hours, younger children have been found to enter a state of 
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ketosis and achieve ketone body turnover rates similar to adults who have fasted for several 
days2,30. This relatively efficient ketone body production and utilization is especially important in 
the days following birth when the brain relies on βHB as its primary source of energy2,30. The 
elderly can generate levels similar to young children after a fast or when adopting a KD29.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Molecular structure of ketone bodies produced in the body.  
 
 
Ketone production, transport, and utilization  
Ketogenesis primarily occurs in the mitochondria of perivenous hepatocytes, with scarce 
amounts being produced in other tissues12. Under typical aerobic conditions, fatty acids and 
glucose are converted to acetyl-CoA by β-oxidation and glycolysis, respectively31,28. Typically, 
acetyl-CoA enters the TCA cycle where it undergoes two decarboxylations and two molecules of 
CO2 are formed
26. Each round of the cycle releases high energy molecules including GTP, 3 
NADH, FADH2, and CoQH2, which produce ATP through oxidative phosphorylation
26. In a state 
β-Hydroxybutyrate Acetoacetate 
Acetone 
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of ketosis, the lack of oxaloacetate available for the TCA cycle is reduced, thereby further driving 
acetyl-CoA towards ketogenesis.  
The process begins with the formation of acetoacetyl-CoA by the condensation of two 
acetyl-CoA molecules in a reversible reaction catalyzed by acetoacetyl-CoA thiolase (AcAcT)29 
(Fig. 2). Mitochondrial HMG-CoA synthase (HMGCS2) then condenses acetoacetyl-CoA with 
another acetyl-CoA to form β-Hydroxy β-methylglutaryl-CoA (HMG-CoA)26,31. Acetoacetate is 
then formed when HMG-CoA lyase (HMGCL) cleaves an acetyl-CoA off of HMG-CoA. AcAc 
can then be reduced to βHB via the catalytic enzyme β-hydroxybutyrate dehydrogenase (BDH1)26. 
Once produced, βHB and a small fraction of AcAc are thought to be transported out of hepatocytes 
by the monocarboxylate transporter SLC16A626. As small (4 carbon) polar molecules, βHB and 
AcAc are readily soluble in the blood stream. Various other monocarboxylic transporters including 
MCT1 and MCT2 are responsible for uptake into target tissues as well as movement of ketones 
across the blood brain barrier1,12 . 
Once taken up by peripheral tissues, ketone bodies undergo ketolysis, which is essentially 
the reversal of ketogenesis27,12. Ketolysis begins with the oxidation of βHB back to AcAc by 
BDH1, which was the last reaction in ketogenesis. At this point, ketolysis diverges from 
ketogenesis and avoids the irreversible reaction catalyzed by HMGCS2 in ketogenesis where 
HMG-CoA is produced12,28. Instead succinyl-CoA donates its CoA to AcAc to form acetoacetyl-
CoA, a reaction catalyzed in most peripheral tissues by 3-ketoacid coenzyme A transferase 
(OXCT1)12,28. These differing enzymatic routes of production and utilization along with the fact 
that OXCT1 is not expressed in the liver, prevent a futile cycle of βHB production and synthesis27. 
Acetoacetyl-CoA thiolase  then converts acetoacetyl-CoA along with a free CoA into two 
molecules of acetyl-CoA, which then enter the TCA cycle for ATP production28,31. The rate 
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limiting step in ketolysis involves Acetoacetyl-CoA thiolase which uses succinyl CoA from the 
TCA cycle as its CoA donor. Its activity is down regulated by AcAc levels equal to or higher than 
5 mM26.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Outline of ketone body production and utilization. Increases in hepatic NEFA 
uptake leads to high rates of β-oxidation, which creates a surplus of acetyl-CoA that is directed 
towards ketogenesis. Ketone body formation is exacerbated by the reduction in hepatic 
mitochondrial oxaloacetate of the TCA cycle, which is directed towards gluconeogenesis, reducing 
its availability for condensation with acetyl-CoA. A small fraction of Acetoacetate production 
enters circulation while most of it is converted to β-hydroxybutyrate, which then enters circulation. 
β-hydroxybutyrate is taken up by peripheral tissues such as the brain and skeletal muscle for energy 
production.  
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Regulation of Ketone Metabolism 
Understanding the regulation of ketone body metabolism which includes aspects such as 
production and utilization is crucial for the understanding of βHB signaling properties12. An 
important point in regulation occurs at the enzyme BDH1, which is responsible for interconverting 
AcAc and βHB in the final step of ketogenesis and the first step of ketolysis31. Ketogenesis is 
regulated through two mechanisms: 1) substrate availability in the form of fatty acids, and 2) 
through the expression of the enzyme HMGCS2 responsible for the synthesis of HMG-CoA32. 
Both mechanisms are regulated by the insulin: glucagon ratio, which controls NEFA mobilization 
from adipose tissue and HMGCS2 expression via transcription factor FOXA2 regulation12,27,28. 
Insulin and glucagon regulate FOXA2 in an opposing manner with insulin signaling leading to the 
inactivation of FOXA2 via phosphorylation and nuclear export. Glucagon activates FOXA2 via 
p300 acetylation allowing it to bind to the HMGCS2 promoter and activate transcription33,34. 
FOXA2 acetylation/activation is regulated in part by SIRT1, a NAD-dependent enzyme along with 
other class 1 and 2 HDACs35. HMGCS2 gene expression is also indirectly regulated by the protein 
complex mammalian target of rapamycin complex 1 (mTORC1)6,36. The inhibition of mTORC1 
is necessary for the activation of fibroblast growth factor 21 (FGF21) and peroxisome proliferator-
activated receptor alpha (PPARα), both of which are needed to induce ketogenesis and increase 
HMGCS2 gene expression6,36. Both PPARα and its target gene FGF21 are dramatically up-
regulated in liver after fasting or by ketogenic diets, and mice lacking either PPARα or FGF21 
have reduced levels of ketogenesis6,36. 
Post-translational regulation of HMGCS2 activity occurs through acetylation and 
succinylation, which the mitochondrial deacetylase SIRT3 and desuccinylase SIRT5 carry out37. 
SIRT3, which is NAD dependent, has been found to regulate many pathways involved in fasting 
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metabolism. In fact, mice lacking SIRT3 displayed lower levels of βHB production upon 
fasting37,38. Many of the enzymes involved in ketogenesis undergo acetylation and contain at least 
one site of interaction with SIRT3 for deacetylation28. Utilization of βHB in peripheral tissues 
involves the transfer of CoA from succinyl-CoA to AcAc to form acetoacetyl-CoA. This process 
therefore reduces the amount of succinyl-CoA available for post translational protein modification. 
SIRT5, a desuccinylase, regulates various mitochondrial pathways related to fasting metabolism. 
The enzyme HMGCS2 has been known to have reduced activity as a result of being 
succinylated2,39. The mechanism driving succinylation is not yet clear, but it’s been suggested that 
there is some level of dependence on succinyl-CoA levels2,39. This is based on the fact that both 
HMGCS2 succinylation and succinyl-CoA abundance in the liver is reduced following treatment 
of rats with glucagon2,39. Succinyl transferase is also not known to be present in mammalian cells 
indicating that succinylation is primarily a non-enzymatic process dependent on local 
concentrations of succinyl-CoA12 .  
βHB and Carbohydrate Restricted Diets  
 Metabolic states where energy intake is restricted or modified in terms of macronutrients 
(e.g. caloric restriction and intermittent fasting) have been shown to metabolically benefit 
individuals suffering from metabolic disease40. These metabolic states are associated with the 
production of ketones and achieving a state of ketosis. Adhering to a ketogenic diet, which restricts 
carbohydrates to just 5% of caloric intake, is the most effective way to achieve ketosis12,40. This 
was demonstrated by a study that placed high-fat-fed mice in one of three conditions: control 
(continued high-fat diet), calorie restriction (25% restriction), or continued high-fat diet with 
ketone supplement replacing 30% of caloric intake to achieve ketosis10. Mice supplemented with 
ketones experienced significantly greater weight loss and increase in energy expenditure compared 
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to the calorie-restriction condition10. This indicates that the most beneficial effects are observed 
with achieving a state of ketosis through adequate carbohydrate restriction or in the case above, 
through adequate ketone supplementation to simulate ketosis31. As we continue to develop a 
greater understanding of the mechanisms involved with ketogenic diets and ketone 
supplementation, interest in using these potential therapies for metabolic issues has grown 
significantly.  
Most of the understanding on the biological effects of KDs originated from rodent studies, 
which observed effects on metabolism resembling those of typical high-fat or western diets (high 
in fat and carbohydrates)41. This resemblance was demonstrated by a study that subjected lean 
healthy mice to a KD, which experienced changes in metabolism similar to mice subjected to a 
high fat diet42. These changes included; increased fasting leptin, hyperglycemia with insulin 
resistance, and a strong induction of genes involved in fatty acid oxidation such as acly-CoA 
dehydrogenase42,43. KDs differ from high fat diets because they cause additional changes to 
metabolism which include; suppressing hepatic expression of enzymes involved in fatty acid 
synthesis such as stearoyl-CoA desaturase 1, low insulin levels, and reduced IGF signaling43–45. 
KDs were also associated with increased activity of PPARα, FGF21, PGC1α, and AMPK, along 
with mTOR repression. A net result of these changes is improved glucose tolerance and insulin 
sensitivity, which is especially apparent in diabetic and obese mice43–45. 
In comparison to rodent studies, there is a relatively limited amount of data on the use of 
KDs in adult humans46. Data gathered so far suggests that individuals on a KD experienced weight 
loss and improved insulin sensitivity47. This is in comparison to other dietary conditions, which 
includes caloric restriction, intermittent fasting, and low fat – high carbohydrate diets47,48. These 
conditions were examined in obese, type 2 diabetic humans, which were randomized to either a 
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low carbohydrate, ketogenic diet (<20 g of carbohydrate daily; KD-fed), or caloric restriction (500 
kcal/day deficit from weight maintenance diet)48. Both groups experienced improvements in 
hemoglobin A1c, fasting glucose, fasting insulin, blood lipid profile, and weight loss48. However, 
the KD-fed group experienced significantly greater improvements in these measurements, which 
led to 95.2% of KD-fed participants to reduce or eliminate diabetic medications compared to 62% 
of participants in the caloric restriction group48.  
Absolute and Optical Configuration of βHB 
The absolute configuration of βHB or chirality is based on the presence of an asymmetric 
carbon with 4 unique substituents is one of a few key features that give a molecule this property. 
Mirror images of a chiral molecule are called optical isomers or enantiomers which can either be 
clockwise (R) or counterclockwise (S)49,50. Directionality is determined based on the prioritized 
order of the 4 unique groups on the chiral carbon. βHB is a chiral molecule at the 3’ hydroxyl 
group, which is an important property to consider when examining its signaling properties and 
possible therapeutic applications1. The R enantiomer (R-βHB) is the usual product in human 
metabolism. The enzyme BDH1 which catalyzes the final step in ketogenesis and the first step in 
ketolysis, introduces the R- βHB specificity. BDH1 does this by catalyzing the reduction of the 
non-chiral 3’ carbonyl on acetoacetate to a chiral 3’ hydroxyl group on βHB. This way BDH1 
ensures that only R- βHB is produced during endogenous βHB production, and only R-βHB can 
be metabolized into acetyl-CoA and ATP49,50. Although S-βHB is not a normal product of βHB 
production, a version of it, S-βHB-CoA has been found in the final step of β-oxidation of fatty 
acids as a transient intermediate. Normally, it does not persist long enough for it to leave the 
mitochondria and enter circulation49,50. Previous studies involving the infusion of radiolabeled S-
βHB, R-βHB, or a mixture of the two into pigs and rats found that most of the S- βHB was 
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converted into R- βHB through an unknown molecular pathway49. There is evidence that S-βHB 
can be metabolized by BDH1 into acetyl-CoA, but at a significantly slower rate compared to R-
βHB51. Infusion of S-βHB or a racemic mixture would result in higher levels of S-βHB being 
measured in circulation and being sustained for longer periods of time compared to R-βHB 
infusions49,50.  
The relative configuration designated by either a D (+) or L (-) is used to describe the form 
of βHB as well. Configuration is based on the direction in which the compound rotates the plane 
of polarized light. Rotation in the clockwise direction designates a D configuration, while rotation 
in the counter-clockwise direction designates a L configuration.  
Research examining the more physiologically active form of βHB refer to it as either R-
βHB or D-βHB1. Configurations become important when designing studies that involve 
supplementing subjects with βHB. The various forms of βHB supplementation include those in the 
ester, salt, and acid form. These forms typically come in a racemic mixture meaning that half of 
the supplement is significantly less active physiologically. This needs to be taken into account 
when creating solutions to attain a desired serum concentration of βHB within a subject1. Most 
studies however will specify the form of supplement and its makeup.  
Regulation of metabolism through βHB signaling  
The ability of an organism to completely adapt to a fasting or low-carbohydrate state 
appears to be in part due to the integration of the various direct and indirect signaling functions of 
βHB. The transition of the body into ketosis is brought on by a two-part mechanism comprised of 
a high fat – low carbohydrate diet, and the resulting production of ketones, primarily βHB. This 
alters the metabolism of peripheral tissues as well as whole-body glucose and fat metabolism12. 
Regulation of gene expression and protein signaling are common themes mentioned when 
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considering the direct and indirect effects of βHB. Histones are at the center of these themes due 
to the role they play in regulating gene expression when subjected to post-translational 
modifications, which include acetylation, succinylation, and β-hydroxybutyrylation1. Histone 
acetylation is a well understood phenomenon capable of broad and specific gene regulation. βHB 
can alter acetylation through direct inhibition of histone deacetylases (HDACs), and indirectly 
through increased acetyl-CoA flux thereby promoting acetyltransferases1.  
Class 1 HDACs are a family of proteins that play a crucial role in regulating gene 
expression of histone and non-histone proteins through deacetylation of their lysine residues1,52. 
Class 1 HDACs which include HDAC1, HDAC2, HDAC3, and HDAC8, are small proteins mainly 
located in the nucleus. They are largely made up of a deacetylase domain and are regularly found 
in large multi-protein regulatory complexes27,28. Increases in the expression of genes regulated by 
class 1 HDACs have been correlated with histone hyperacetylation, and so increases in class 1 
HDAC activity has been shown to suppress gene expression. Numerous non-histone proteins such 
as MYOD1, NF-κB, TP53, MYC, etc., also undergo HDAC regulation52,53. βHB has been found 
to inhibit HDAC1, HDAC3, and HDAC4 which are a part of classes 1 and 2a deacetylases. 
Treatment of certain cell culture lines such as macrophages and neurons with βHB have shown a 
dose-dependent induction of hyperacetylation, specifically at lysine residues 9 and 14 on histone 
H331,39. Studies involving fasting mice showed that increases in histone acetylation in numerous 
tissues including the liver, correlated with increases in plasma βHB levels. βHB treatment of mice 
using an osmotic pump resulted in histone hyperacetylation, most notably in the kidney, as well as 
changes in the expression of genes such as forkhead box O3 (Foxo3a)44,54. HDAC1 and HDAC2 
have been found on the promotor of Foxo3a, indicating that its induction is related to HDAC 
inhibition. Knockdowns of both HDAC1 and HDAC2 relieved HDAC-mediated suppression on 
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Foxo3a with βHB treatment resulting in hyperacetylation of histones at the Foxo3a promoter55,56. 
The mechanism controlling HDAC inhibition is considered to center around competitive inhibition 
of the catalytic site. Studies examining the inhibition of human class 1 HDAC8 found that various 
hydroxamic and carbonic acid inhibitors bound to the catalytic zinc found in the hydrophobic 
active site1,57. βHB is structurally similar to butyrate, a well-known inhibitor of HDACs, differing 
only in the oxidation state of the 3’carbon. With similar kinetics to competitive inhibitors, the 
carboxylic acid of βHB is thought to chelate the catalytic zinc in a manner similar to the acidic 
groups on other HDAC inhibitors1,57. Increasing oxidation may be a barrier to binding within the 
hydrophobic channel of the HDAC active site, and as expected, the IC50 of βHB for HDAC1 
increases with the oxidation state53.  
HDAC inhibition by βHB could affect the pathogenesis of type 2 diabetes through direct 
regulation of HDAC-dependent glucose metabolism and by promoting resistance to oxidative 
stress58. Studies in knockout mice have shown that class 1 HDACs play a key role in regulating 
metabolism, especially in models of metabolic disease1,12. HDAC3 for example, regulates 
gluconeogenic genes and HDAC3 knockout mice displayed reduced insulin and fasting glucose 
levels44,52. Mice treated with βHB resembled HDAC3 knockout mice and remained essentially 
normal metabolically while on a high fat diet59. This supports the idea that βHB is associated with 
lower insulin and glucose levels, improved glucose tolerance, and prevent weight gain60,61. βHB 
can also provide these benefits to mice already obese due to a high fat diet62.  
SAHA, another class 1 HDAC inhibitor, administered to a diabetic mouse model improved 
insulin sensitivity, lowered serum glucose levels, and reduced body fat63. The mechanism 
underlying class 1 HDAC inhibition and these metabolic effects could be an up-regulation of 
PGC1α in various tissues by relief of HDAC3-mediated transcriptional repression62,63. FGF21 
16 
 
transcription is up-regulated in a similar fashion through HDAC3 inhibition via βHB, thereby 
triggering ketogenesis in obese mice64. The effects of HDAC3 inhibition has not been fully 
explored yet, let alone inhibition of other class 1 HDACs in relation to metabolic regulation65.  
The micro and macro vascular complications of type 2 diabetes such as cardiovascular 
disease is thought to be partially caused by increased oxidative stress brought on by various 
pathways such as the activation of protein kinase C66. With this in mind, the newly discovered role 
of βHB in possibly suppressing oxidative stress could be relevant to managing the complications 
of type 2 diabetes66. As previously described, βHB activates FOXO3 transcription and increases 
downstream antioxidant gene expression via HDAC inhibition44. This is all associated with 
protection of the mouse kidney from oxidative stress and damage, which is in accordance with 
studies that have suggested a protective role for βHB and HDAC inhibition against oxidative 
and/or ischemic stress44. Specifically HDAC 2, which is a class 1 HDAC, has abnormally increased 
activity in the kidney of diabetic mice to protect against the oxidative stress caused by transforming 
growth factor beta 1 (TGFβ)67. Similar to a ketogenic diet, βHB  administration has shown 
protective effects against ischemic neuronal death, myocardial damage, and the effects of 
hydrogen peroxide, which is a source of free radicals67,68. A possible mechanism for the protective 
antioxidant effects of βHB in type 2 diabetes and associated vascular complications could be an 
induction of antioxidant genes through βHB-induced HDAC inhibition1,69. Even with the wide 
spread role that HDACs play in regulating changes in gene expression in response to stimuli, the 
exact mechanisms behind this regulation have yet to be studied systematically1. 
Succinylation of lysine residues is another post translation protein modification controlled 
indirectly by βHB. During the process of ketolysis through which βHB is converted to acetyl-CoA, 
succinyl-CoA donates its CoA to AcAc to form acetoacetyl-CoA. This process thereby reduces 
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the amount succinyl-CoA available for succinylation1,31. Histone β-hydroxybutyrylation remains 
largely unstudied, but should receive strong interest because of its ability to respond to changes in 
metabolism by modifying gene expression accordingly31. 
β-Hydroxybutyrylation of proteins 
In addition to inhibiting regulatory enzymes involved in post-translational modifications 
such as HDACs, βHB can itself directly modify proteins at the post-translational level1,69.  Histones 
that have undergone β-hydroxybutyrylation at specific lysine residues are referred to as KβHB, 
and they have been detected by mass spectrometry in yeast, fruit fly, mouse, and human cells1,69. 
Western blot analysis revealed increased in histone KβHB in human cells, an effect that was 
proportional to exogenous βHB treatment1,69. This was also detected in mouse liver, which was 
proportional to increases in plasma βHB levels under conditions of diabetic ketoacidosis. In the 
case of both humans and mice, a 40-fold increase in the relative abundance of KβHB was caused 
by fasting69. At least 40 histone lysine sites have been identified that are capable of β-
hydroxybutyrylation, some of which are crucial for transcriptional regulation such as on the 
histone H3K91,69. Histone H3K9 has been shown to be associated with the promotors of actively 
transcribed metabolic genes through chromatin immunoprecipitation (ChIP)1,69.  When RNA gene 
expression data was compared with ChIP data from fasted mouse livers, there was a strong 
correlation between genes with the greatest increase in KβHB at the promoter and those with the 
greatest increase in expression. H3K9 KβHB has been associated with increased gene expression 
independent of other activation markers such as acetylation and methylation, suggesting an 
independent function which isn’t yet clear69,54. It is unknown whether non-histone proteins can 
undergo β-Hydroxybutyrylation and whether this only occurs in the liver. It is also unclear if any 
enzymes participate in the addition and/or removal of βHB from lysine residues, which would 
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provide an opportunity for fine-tuned regulation and specific targeting of β-hydroxybutyrylation. 
Overall, β-hydroxybutyrylation may be a key point in gene regulation associated with fasting and 
other conditions linked to increased βHB levels1,54,69. 
Acetyl-CoA as a substrate for protein acetylation  
The catabolism of βHB ends in its conversion to acetyl-CoA, which would overall raise 
acetyl-CoA levels in target tissues and facilitate enzymatic and non-enzymatic protein 
acetylation12. This post-translational protein modification would complement the HDAC 
inhibition by βHB and together may have broader effects on various cellular components and 
functioning12.  Acetylation of proteins in the mitochondria is especially sensitive to increases in 
acetyl-CoA, as conditions associated with increased lipid utilization such as high-fat diets, fasting, 
and dietary restriction, increase mitochondrial protein acetylation70. This increase in mitochondrial 
protein acetylation occurs despite the fact that neither acetyltransferases nor βHB inhibited 
HDACs entering the mitochondria70.   
 Increased acetyl-CoA pools also affect acetylation of nuclear proteins. Mitochondrial 
acetyl-carnitine is the source of acetyl-CoA used for nuclear histone acetylation71. The citrate 
shuttle, regulated by citrate synthase inside the mitochondria and ATP citrate lyase in the 
cytoplasm, is responsible for the export of acetyl-CoA from the mitochondria72. An alternate 
pathway for mitochondrial export of acetyl-CoA is via the enzymes carnitine acetyl transferase 
and carnitine/acyl carnitine translocase72. A muscle specific knockout of carnitine acetyl 
transferase in mice resulted in reduced glucose tolerance and insulin sensitivity73.  This study 
provided a clear example of the importance of intracellular acetyl-CoA transport to overall 
metabolic health as well as the potential impact βHB has on acetyl-CoA levels72,73.  
19 
 
βHB receptors  
 Of the various G-protein coupled receptors (GPCRs) that bind to fatty acid ligands and, 
there are at least two that also bind βHB 12,74. One is hydroxycarboxylic acid receptor 2 (HCAR2), 
which has been shown to bind and be activated by βHB leading to reduced lipolysis in 
adipocytes12,75. This may represent a type of feedback mechanism to aid in regulating the 
availability of non-esterified fatty acids (NEFAs) in the circulation. Without this mechanism, 
unregulated lipolysis in adipocytes has been shown to greatly elevate NEFAs in the circulation 
and contribute to insulin resistance75,76. HCAR2 activation has also been shown to decrease plasma 
glucose, thereby contributing to improve glycemic control and alleviate some of the vascular 
complications in type 2 diabetic patients75,76.  
Free fatty acid receptor 3 (FFAR3) is another GPCR highly expressed in sympathetic 
ganglions31,77. Some studies have reported that βHB binding to FFAR3 suppressed sympathetic 
tone and reduced heart rate, whereas other studies have found the opposite77,78. Thus, it may be 
that βHB binding to FFAR3 is responsible for sympathetic depression during fasting, although 
further studies are required to test this hypothesis.  
Cytoplasmic and mitochondrial NAD: NADH equilibrium   
The ratio between NAD and NADH in cytoplasmic and mitochondrial pools is emerging 
as an important aspect of cellular metabolism1,79. This ratio is first altered when βHB is utilized in 
peripheral tissues such as skeletal muscle, where it is converted to AcAc by mitochondrial BDH1 
using 2 NAD as a cofactor, which generates 2 NADH31. This differs from the metabolism of 
glucose which converts 4 NAD into NADH, 2 of which are in the cytosol31. High glucose 
utilization would lead to a decrease in NAD relative to NADH. Combined with the fact that 
cytoplasmic NADH is shuttled into the mitochondria for ATP generation, the NAD: NADH ratio 
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may be further imbalanced79. With mitochondrial and cytoplasmic pools being relatively distinct, 
preservation of the cytoplasmic pool can have important effects on cellular metabolism80,81. 
Preservation of these discrete pools and maintain the NAD: NADH balance would affect the 
functioning of enzymes that use NAD as a cofactor80,81. An example of this is the enzyme PARP 
that uses NAD in the process of repairing single strand DNA breaks. Depleted cytoplasmic pools 
of NAD would leave PARP with an inadequate NAD supply, which has been associated with 
metabolic and age-related diseases79,82. This includes atherosclerosis, other cardiovascular 
disorders, dementia, diabetes, arthritis, and osteoporosis79,82.Conversely, replenishment with 
nicotinamide mononucleotide improves glucose tolerance in high-fat fed mice80,81. This indicates 
that NAD sparing through βHB metabolism may have important consequences for metabolic 
diseases and diabetes through changes in cellular metabolism12.   
Protein Kinase B (AKT)   
Skeletal muscle plays an important role in glucose metabolism due to the fact that it is the 
primary site of insulin mediated glucose uptake and makes up approximately 40% of body weight 
in humans. With this in mind, it is crucial that the cellular metabolic pathways related to glucose 
metabolism and how they may be affected by βHB, be examined. Two major metabolic pathways 
related to insulin signaling and glucose homeostasis83,84. The first one is the PI3K-AKT pathway 
that is activated by insulin signaling83. The PI3K-AKT pathway is considered to be the primary 
pathway directly stimulated by insulin signaling that mediates energy metabolism and insulin 
sensitivity(fig. 3)83,84. The phosphatidyl inositol 3 kinase (PI3K)-AKT pathway is engaged upon 
insulin binding to its receptor on the plasma membrane. This leads to auto-phosphorylation and a 
conformational change of the insulin receptor (IR) with subsequent recruitment and 
phosphorylation of the insulin receptor substrate (IRS) on key tyrosine residues83,84.  
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These residues are recognized by PI3K via its p85 regulatory subunit, which allows its 
catalytic subunit, p110 to phosphorylate phosphatidylinositol (4,5) bisphosphate (PI(4,5)P2). As a 
result, phosphorylate phosphatidylinositol (4,5) triphosphate (PI(3,4,5)P3) formed and anchored to 
the plasma membrane83,84. PI(3,4,5)P3 is then able to bind directly to proteins with a pleckstrin 
homology, which include AKT and 3-phosphoinositide-dependent protein kinase 1 (PDK1). The 
binding of AKT leads to a conformational change which exposes phosphorylation sites Thr308 
and Ser473. PDK1 which is also bound to PI(3,4,5)P3, phosphorylates AKT at Thr308
85. Complete 
activation of AKT requires phosphorylation at Ser473 which is regulated by mammalian target of 
rapamycin complex 2 (mTORC2)86. Once activated, AKT phosphorylates and inhibits AS16086. 
AS160 is a Rab GTPase activating protein that converts the active GTP bound form of Rab into 
the non-active GDP bound form. Rab proteins regulate many steps of membrane trafficking, 
including vesicle formation, vesicle movement along actin and tubulin networks, and membrane 
fusion85,86. RabGTPs stimulate the translocation of vesicles carrying GLUT4 transporters to the 
plasma membrane where they fuse85,86. This allows GLUT4 transporters to localize to the plasma 
membrane and increasing glucose uptake85,86.  
5′ AMP-activated protein kinase (AMPK)  
AMP-activated protein kinase (AMPK) has wide range of functions ranging from 
mitochondrial biogenesis and angiogenesis, control of food intake and energy expenditure, to 
regulation of gene transcription85,87. It is an energy sensing enzyme that is activated by anabolic 
processes that increase the intracellular AMP:ATP ratio, which can occur due to either increased 
of energy expenditure or limited ATP production88. Once activated, catabolic processes that 
increase ATP production are stimulated (e.g. glucose and fatty acid oxidation), whereas ATP-
consuming anabolic pathways are suppressed (e.g. cell growth and proliferation)85,88. AMPK 
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activation has been shown to counteract many physiological abnormalities such as insulin 
resistance, inflammation, and ectopic lipid deposition, especially in skeletal muscles87,89. These 
abnormalities are typically dealt with in part by diet regiments including caloric restriction, 
intermittent fasting, and high fat-low carbohydrate (ketogenic) diets, which have been associated 
with AMPK activation in rodent and human models1,87. This is demonstrated in a study in which 
rats were subjected to either caloric restriction, the AMPK activator AICAR, or regular 
exercise87,89. Caloric restriction was found to increase AMPK activity to a degree resembling that 
of the AICAR and regular exercise conditions87,89. Compared to caloric restriction, KDs also 
increase AMPK activation. Human work has found that KD induced activation occurs in various 
tissues, notably skeletal muscle via an increase in SIRT1 expression87,90. βHB has been shown to 
increase SIRT1 expression, which would become significant while on a KD. LKB1 is one of the 
proteins that are deacetylated by SIRT1, which activates it allowing it to phosphorylate and 
activate of AMPK87,90.  
AMPK is a heterotrimeric enzyme comprised of one catalytic subunit (α), and two 
regulatory subunits (β and γ)88. Its activation can be achieved by allosteric and covalent 
mechanisms88,87. Under conditions of lower ATP levels, AMPK is allosterically activated by ADP 
or AMP binding to the γ subunit. Bindings results in a conformational change, which opens AMPK 
up to phosphorylation88,87. AMP and ADP are also capable of binding to sites meant for nucleotides 
further allowing AMPK to respond to a variety of physiological changes88,87.  
AMPK activation is also regulated by NAD+ levels with SIRT1 being key to this pathway88,87. 
SIRT1 is a deacetylase that uses NAD+ as a cofactor88,87. Under conditions of an increased 
NAD+/NADH ratio, NAD+ allosterically activates SIRT1 which goes on to deacetylate the 
nuclear bound serine/threonine kinase LKB188,87. After deacetylation, LKB1 moves into the 
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cytoplasm where it forms a complex with its allosteric activators, STRAD and MO2591. This leads 
to the second mechanism of AMPK activation, which is covalent activation through the 
phosphorylation of Thr172 by LKB1 or CAMKK (fig. 3)91. LKB1 is able to phosphorylate AMPK 
only once it is complexed and in the cytoplasm91. Intracellular Ca+2 levels are another regulator of 
metabolic pathways in muscle cells acting as an allosteric activator of AMPK. Protein kinases can 
be regulated by Ca+2 levels through calmodulin (Cam) kinases88,87. These Cam-dependent protein 
kinases (CamKs) are regulated by other CamKs referred to as (CAMKKs) which also possess the 
ability to phosphorylate AMPK at Thr17288,87. Once active, AMPK, like AKT, phosphorylates 
AS160 thereby deactivating it and allowing Rab to stay in its active GTP bound state and promote 
GLUT4 translocation and fusion to the plasma membrane88,87.  
Glycogen Synthase Kinase 3 (GSK3) and Glycogen Synthase (GS)  
Glycogen synthesis begins with the phosphorylation of glucose to glucose-6-phosphate 
(G6P) via hexokinase. G6P is then converted to glucose-1-phosphate (G1P) by 
phosphoglucomutase. G1P can then be activated via the addition of a uridine nucleotide to form 
UDP-glucose, which is catalyzed by UDP-glucose pyrophosphorylase 2 (UGP2). Glycogen 
synthase (GS) then catalyzes the addition of the glucose within UDP-glucose to glycogen 
polymers92. GS is upregulated allosterically by glucose-6-phosphate while phosphorylation by 
glycogen synthase kinase 3 (GSK3) leads to inactivation92,93. GSK3 itself is a downstream target 
of the AKT/PI3K pathway and is therefore regulated in part by insulin signaling (fig. 3)84. Insulin 
signaling leads to the activation of AKT which phosphorylates Ser21 of GSK3α and Ser9 of 
GSK3β resulting in transient inactivation93. In the absence of insulin, phosphorylation of Ser21 and 
Ser9 is reversed by the protein phosphatases PP2A and PP1 allowing GSK-3 to remain active until 
further stimulation of the tissue by insulin or other PI3K agonists84,93. With GSK3 inactivated, it 
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is unable to phosphorylate GS allowing it to remain active and catalyze glycogen synthesis (fig. 
3)84,93. In the case of GS being phosphorylated, the same phosphatases that act on GSK3 (PP2A 
and PP1) act on GS thereby activating it84,93. GS is also capable of being phosphorylated by AMPK 
and protein kinase A (PKA). Insulin signaling leads to PK1 activation which is responsible for the 
phosphorylation and activation of PKA84,93.  
Insulin signaling along with the glucose metabolism is affected by dietary changes 
including caloric restriction, intermittent fasting, and high fat-low carbohydrate (ketogenic) diets. 
KDs for example have been shown to improve signaling, glucose tolerance, and overall glucose 
metabolism. Considering the signaling capabilities of βHB and its potential to play a role in 
altering glucose metabolism, changes in glycogen synthesis as a result of βHB are possible. 
Through HDAC regulation or post-translational modification, βHB supplementation may alter the 
gene expression or activity of any one of the proteins involved in the glycogen synthesis pathway. 
An example of such targets are the phosphatases PP2A and PP1 which help regulate the activity 
of GS and GSK3 through dephosphorylation84,93.  
 
 
  
25 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Signaling pathways for insulin and contraction stimulated glucose transporter 4 
(GLUT4) translocation in muscle. Insulin stimulates AKT through phosphoinositide-dependent 
protein kinase-1 (PDK1) and mammalian target of rapamycin complex-2 (mTORC2). Activated 
AKT phosphorylates AS160, which inhibits its Rab-GTPase-activating protein (GAP). Inhibition 
of GAP promotes conversion of less active GDP-loaded Rab to more active GTP-loaded Rab. The 
more active GTP-loaded Rab then allows GLUT4 storage vesicles to move to and fuse with the 
plasma membrane. Energy depletion (elevated AMP/ATP ratio) through contraction and elevated 
intracellular [Ca2+] leads to activation of AMP-activated protein kinase (AMPK) via LKB1 and 
Ca2+calmodulin-dependent protein kinase kinase (CaMKK), respectively (and other Ca2+-
regulated protein kinases). Activated AMPK phosphorylates AS160 adding further regulation to 
GLUT4 membrane fusion. GSK3 is regulated by insulin signaling via phosphorylation by AKT, 
which leads to its inactivation. It is unable to phosphorylate GS allowing it to remain active and 
catalyze glycogen synthesis. AMPK is also capable of phosphorylating GS thereby deactivating it 
and reducing glycogen synthesis.  
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Carnitine Palmitoyl Transferase 1 (CPT1) 
Carnitine palmitoyltransferase I (CPT1) is an integral membrane protein with three 
isoforms, CPT1A, CPT1B, and CPT1C. Isoform CPT1A is found on the mitochondria of all cells 
throughout the body, except for skeletal muscle and brown adipose tissue94,95. CPT1B is the 
isoform found in brown adipose tissue as well as heart and skeletal muscle. Little is known about 
the CPT1C isoform, which is expressed in the brain and testes. CPT1 is an integral membrane 
protein that possesses transmembrane regions allowing it to interact with the outer mitochondrial 
membrane (Fig. 4)94. CPT1B is a part of the carnitine palmitoyl transferase system which is 
essential for the beta-oxidation of fatty acids94,95. The system is responsible for transporting 
activated fatty acids outside the mitochondria into the mitochondrial matrix where they are 
oxidized94,95. Long chain fatty acids such as palmitoyl-CoA, unlike short and medium chained 
fatty acids, are unable to freely diffuse through the inner mitochondrial membrane thus requiring 
the shuttle system94,95. CPT1B is the first component of the carnitine palmitoyl transferase system 
and is responsible for catalyzing the rate limiting step of forming palmitoylcarnitine by transferring 
the acyl group from coenzyme-A to carnitine96. At this point palmitoylcarnitine is in the 
intermembrane space where a translocase then shuttles it into the mitochondrial matrix95,96. Once 
in the matrix, palmitoylcarnitine is converted back into palmitoyl-CoA. CPT1 activity is regulated 
by malonyl-CoA with the CPT1B isoform being significantly more sensitive than the CPT1A 
isoform95,96. Acetyl-CoA carboxylase (ACC) is the enzyme that catalyzes the formation of 
malonyl-CoA from acetyl-CoA making it an important regulator of fatty acid metabolism95,96.  
The reaction catalyzed by ACC is comprised of two half reactions; the ATP-dependent 
carboxylation of biotin with bicarbonate to form carboxybiotin, followed by transfer of the 
carboxyl group from carboxybiotin to acetyl-CoA to form malonyl-CoA97. Studies have suggested 
that diverse physiological conditions which include various diets, can affect fatty acid synthesis 
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via alterations in ACC activity98. AMPK for example is activated by AMP signifying a low energy 
state in the cell. This triggers a response by AMPK that maximizes ATP production and reduces 
anabolic processes such as fatty acid synthesis via phosphorylation and deactivation of ACC6. As 
mentioned above, AMPK activity can be upregulated in a ketogenic condition, possibly due to the 
activity of βHB.  
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Figure 4: Schematic representation of b-oxidation pathway. The rate-limiting step in b-
oxidation is the transport of activated fatty acids (fatty acyl-CoA) into mitochondria. This is 
catalyzed by CPT1B, which transfers carnitine for CoA, forming fatty acyl-carnitine. Once inside 
the mitochondrial matrix, CPT2 reforms fatty acyl-CoA, which enters the b-oxidation cycle, 
generating acetyl-CoA molecules from which ATP is generated through the TCA cycle and 
electron-transport chain.  
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Whole-body effects of a KD and exogenous ketone supplementation in rodents 
 The effectiveness of the KD as a treatment for various aspects of metabolic disease and 
ketone supplementation as a possible KD substitute has only recently begun to be investigated. 
Work focused on the cellular mechanisms responsible for the observed effects of KDs and ketone 
supplementation relative to work done with human and animal models. Studies in rodents found 
that KD effectively stimulated weight loss along with changes in body composition. Garbow et al. 
found that after 12 weeks of KD, there was significantly lower weight gain compared to mice on 
various diets including chow-fed, high carbohydrate, and high-fat western diet. Lean mass was 
found to decrease significantly in KD-fed mice compared to mice on the other diets. The decrease 
in lean mass could be attributed to the protein content of the KD comprising only 4.5% of the 
caloric intake leading to muscle catabolism.  
Jornayvaz et al. showed that mice fed a KD for 5 weeks gained significantly less weight 
than regular chow-fed mice due to increased energy expenditure. KD-fed mice also suffered from 
hepatic insulin resistance reflected by decreased suppression of hepatic glucose production during 
a hyperinsulinemic-euglycemic clamp99. The clamp indicated that the KD-fed mice required 
glucose infusion rates that were 47% lower than in controls.  Hepatic insulin resistance could be 
attributed to various factors, including more than a 3-fold increase in hepatic DAG content 
resulting in protein kinase C activation (PKC). This in turn decreases insulin signaling through 
IRS-2 phosphorylation regulation. KD-fed mice developed a decrease in whole-body glucose 
disposal, which was likely a result of a change in body composition99. Although these mice had 
lower body weights compared to controls, they had higher body fat content99. There was also a 
decrease in lean body mass, which would directly lead to a decrease in insulin stimulated glucose 
uptake. Lean muscle loss could be attributed to the low protein (4.5%) and carbohydrate (0.4%) 
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content of the KD. This would lead to increased proteolysis where a portion of amino acids would 
be used for gluconeogenesis99. Other measures of insulin sensitivity were used as well including 
the homeostasis model assessment of insulin resistance (HOMA-IR) (40) and the quantitative 
insulin sensitivity check index (QUICKI), which both rely on fasting concentrations of glucose 
and insulin99. With the KD-fed mice exhibiting lower basal insulin and glucose levels, the HOMA-
IR and QUICKI suggested improved insulin sensitivity. This is in comparison to the 
hyperinsulinemic-euglycemic clamp which administered insulin and glucose in order to balance 
glucose uptake and infusion99. The possible role of KD in inducing insulin resistance is 
nevertheless controversial. Indeed, several authors reported that long term KD fed mice had normal 
glucose tolerance, lower baseline insulin levels and improved insulin sensitivity100. 
Another study examined the long term effects of KD feeding in mice over the course of 80 
weeks101. Weight loss was seen in the first 18 weeks, but returned to baseline and increased 
afterwards101. Weight gain was less than controls as a result of overall reduced lean and fat mass. 
The KD-fed mice also increased energy expenditure and RER, which indicated enhanced use of 
fatty acids as an energy substrate101. A recent study looked at the effects of KD on exercising and 
sedentary rats compared to standard chow-fed control animals102.  After 6 weeks on the diet, KD-
fed rats had smaller adipocytes in visceral fat, 25% lower body mass, 80% lower levels of serum 
insulin, 50% lower levels of plasma glucose, 55% lower levels of plasma triglycerides, and 20% 
lower levels of total cholesterol relative to levels seen before beginning the KD feeding102. Despite 
the KD-fed rats being separated into sedentary and exercised groups, they both displayed similar 
results102. Exercising KD-fed rats did show 40% lower serum βHB levels compared to KD-fed 
sedentary rats possibly due to low intensity exercise having a greater reliance on ketone and fat 
oxidation for fuel102.  
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These results suggest that some of the physiological changes brought about by the KD such 
as body fat regulation through changes in adipose tissue mass and cell size, may be similar to the 
effects of exercise. Increased serum ketone levels may play a role in these changes although it is 
unclear how significant102. Another study determined whether orally ingesting βHB salts could 
increase ketonemia in Wistar rats without any other dietary changes5. βHB salts were administered 
acutely by gavage or chronically by drinking water over 4 weeks. Glucose overload was done at 
the same time to suppress any potential endogenous ketogenesis to isolate the effects of the βHB 
salts5. In both conditions, ketonemia increased along with increased HDL concentrations, 
decreased LDL/HDL ratio culminating in an improved blood lipid profile. An overall decrease in 
adipocyte volume and serum lipolysis byproducts, which include; triacylglycerol (TAG), HDL, 
LDL, and NEFAs was also found5. These results support the idea that ketonemia can be induced 
through βHB supplementation and as a result, physiological changes are possible.   
 
Whole-body effects of a ketogenic diet and exogenous ketone supplementation in humans 
In humans, the KD has been shown to be an effective weight loss therapy, although the 
mechanisms at work are still unclear. Proposed mechanisms include reduced caloric intake, 
increased use of proteins as a source of fuel, energy demanding gluconeogenesis, and increased 
satiety36. Investigating these mechanisms often involved comparing the KD to other diets such as 
one that is hypocaloric. Studies have shown KD  reduces ghrelin levels and appetite, whereas  a 
hypocaloric diet  typically causes an increase in these levels103. This was confirmed by a  study 
conducted on 132 severely obese patients with a high prevalence of T2D or metabolic syndrome 
where the  participants lost more weight while on the KD compared to other diets104. Other authors 
compared different diets in the same group of patients eating alternatively a KD, a low-
carbohydrate non-KD, and a normal Mediterranean diet105. Significant weight loss and decreases 
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in body fat percentage was found in KD-fed participants compared to participants on the other two 
diets105. Moreover, if the patients were compliant to the prescribed Mediterranean diet, which was 
a relatively strict 1800 kcal/day during the maintenance period, no weight regain was observed at 
12 months105. Another study compared a low-carbohydrate high unsaturated fat diet to a high-
carbohydrate low-fat diet in addition to a structured exercise with obese type 2 diabetes patients106. 
Both groups experienced similar weight loss of approximately 9% with a trend towards regaining 
the weight seen only in the low-carbohydrate group at 52 weeks106. Jabekk et al., examined the 
effects of resistance training in combination with either a KD or a control diet, on body 
composition in overweight women107. The KD group lost fat mass without experiencing a 
significant alteration in lean mass, while the other group gained lean mass without a significant 
change in fat mass107. In terms of effects on glucose metabolism, a study in obese type 2 diabetic 
patients fed a KD saw significant improvement in fasting glucose levels was seen after 12 weeks 
and continued after 56 weeks108. A similar study only saw a short-term decrease in HbA1c at 6 
months, which was not sustained at 24 months109. Comparing the diets used in these two studies, 
the latter used a less intense KD with a slightly higher carbohydrate intake. This suggests that 
lower intensity KD can be adapted to leading to a decrease in the benefits seen over time.  
Stubbs et al., examined whether exogenous ketones were an effective way to achieve 
ketosis as an alternative to a high-fat, low-carbohydrate “ketogenic” diet that are typically difficult 
to adhere to. Healthy human volunteers took part in three randomized metabolic studies of drinks 
containing a ketone ester (KE); (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, or ketone salts (KS); 
sodium plus potassium βHB110. In the first study 15 participants consumed KE or KS drinks that 
delivered ∼12 or ∼24 g of βHB both of which elevated plasma βHB concentrations and returned 
to baseline within 3 to 4 hours110. Urinary excretion of βHB was less than 1.5% of the total βHB 
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ingested. In the second study, the effect of a meal before a KE drink on plasma βHB concentrations 
was determined. Food lowered peak plasma βHB concentration by 33% but did not alter 
acetoacetate or breath acetone concentrations. All ketone drinks lowered blood glucose, free fatty 
acid and triglyceride concentrations, and had similar effects on blood electrolytes110. The final 
study compared different methods of βHB administration. Patients were given KE over 9 hours 
using three drinks at 3-hour intervals or through continuous nasogastric infusion after an initial 
bolus. Both results methods were found to be nearly identical in terms of total appearance of βHB 
in the blood111.  
One study investigated the effects of raising plasma βHB levels through ingestion of salts 
on cycling performance and substrate oxidation11. Ten healthy adult males were recruited and on 
experimental days, fasted participants consumed either 0.3 g/kg βHB ketone salts or a flavor-
matched placebo at 30 min prior to engaging in cycling exercise11. Subjects completed steady-state 
exercise at 30%, 60%, and 90% ventilatory threshold (VT) followed by a 150-kJ cycling time-
trial. Plasma βHB levels were elevated starting from baseline throughout the entire ketone 
condition11. RER was lower at 30% and 60% VT in the ketone compared with control condition 
with total fat oxidation being greater in the ketone condition versus the control11. Average time 
trial power output was 7% lower in the ketone condition. Overall these results indicated that 
ingestion of βHB salts prior to exercise increased fat oxidation during steady-state exercise while 
impairing high intensity exercise performance11.  
Little to no work done to examine the tissue specific changes or cellular mechanism 
responsible for physiological changes seen when on a KD. Little has attention has been given to 
the ketones such AcAc and especially βHB that are produced when individuals enter a state of 
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ketosis when on a KD. βHB for example has been found to possess signaling potential worth 
exploring on a cellular level where the metabolism of cells can be affected. 
Objectives and Hypothesis  
 
The general objective of this study was to determine if βHB can mimic the effects of a KD 
on skeletal muscle glucose and fat metabolism. To accomplish this, an in-vitro model with L6 
muscle cells supplemented with various βHB in a dose response treatment will be used. This will 
determine which physiologically relevant concentrations of βHB would be capable of inducing 
changes in glucose and fat metabolism by measuring glucose uptake. The minimum effective dose 
of βHB would then be examined in subsequent functional assays done on cells subjected to a time 
course treatment. Based on the literature, we know that insulin sensitivity and whole-body glucose 
clearance improves when on KD. Therefore, we hypothesize that glucose uptake would increase. 
In addition to an increase in glucose within the cell, we expect glucose utilization pathways such 
as glycogen synthesis, glucose oxidation, and lactate production to also be elevated. 
According O’Malley et al., we know βHB salt supplementation increased fat oxidation in 
human males despite differences in exercise routines. Therefore, we expected that palmitate 
oxidation would increase with βHB supplementation.  
In addition to looking at the functional implications of βHB supplementation, we wanted 
to examine key proteins involved in glucose and fat metabolism. Using western blot analysis, we 
would measure AKT and AMPK (phosphorylated and unphosphorylated states) which play a role 
in glucose uptake. We expect an elevation in PAKT and PAMPK levels to explain an increase in 
GLUT4 translocation to the plasma membrane and therefore glucose uptake. Proteins involved in 
the glycogen synthesis pathway such as GSK3 and GS (phosphorylated and unphosphorylated 
states) would be measured. Changes in the expression levels would cause a change in the activity 
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levels and impact the ability of the cells to synthesis glycogen. Finally, we will be examining 
CPT1β which we expect to see an increase, as it is involved in the rate limiting step of fatty acid 
oxidation.  These experiments would provide a better understanding of the mechanisms involved 
in the various pathways that βHB would impact. With better insight, we can evaluate the potential 
of βHB supplementation as a viable alternative to the KD. 
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Abstract 
 
This study investigated the effects of the ketone body β-hydroxybutyrate (βHB) on glucose 
and fat metabolism in skeletal muscle cells. To accomplish this, L6 muscle cells were incubated 
with various βHB concentrations (0.5, 1.0, 1.5, 20, and 2.5mM) for 1, 3, and 5 days. Here, we 
report that βHB significantly increased glucose uptake and its metabolism in L6 muscle cells. In 
fact, time course analysis revealed that as early as 1 day of exposure to βHB (1mM) significantly 
enhanced basal and insulin-stimulated glucose uptake (1.6-fold), glycogen synthesis (1.3-fold), 
glucose oxidation (1.5-fold), and lactate production (1.3-fold) in skeletal muscle cells. Even 
though carnitine palmitoyl transferase 1 (CPT1) content and AMP-activated protein kinase 
(AMPK) phosphorylation significantly increased, no alteration was found in palmitate oxidation 
with βHB treatment. Surprisingly, protein kinase B (AKT) phosphorylation was significantly 
reduced in muscle cells exposed to βHB. In summary, βHB increased AMPK phosphorylation and 
enhanced glucose uptake without altering fatty acid oxidation in skeletal muscle cells.   
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Introduction  
 
Ketogenic diets (KDs) are characterized by high and low contents of fat and carbohydrates, 
respectively1.  These diets have been known for their therapeutic value in the treatment of 
neurological disorders such as epilepsy2. In recent years, the popularity of KDs has increased due 
to the fact that they can also be beneficial in the treatment of metabolic diseases primarily through 
improvements in whole-body glucose control2. Although KDs have been shown to have broad 
therapeutic potential, patient compliance can be challenging2,3. This is because along with severe 
dietary restriction and unpalatability of meals associated with KDs, those who are on a KD deal 
with possible hypoglycemic episodes and intolerance to high fat ingestion3,4. In this context, it has 
been suggested that oral supplementation of ketones may mimic a metabolic state of ketosis 
without any of the shortcomings of a typical KD, therefore serving as a practical alternative3,5. β-
Hydroxybutyrate (βHB), acetoacetate, and acetone are the ketones produced by the body. 
However, βHB considered the most functionally relevant because of its signaling capabilities and 
the fact that it is less likely to undergo degradation and be eliminated relative to than acetoacetate 
and acetone6,7.  
Therefore, chronic supplementation of βHB has been suggested as an alternative approach 
to create ketogenic conditions without having to adhere to a typical KD. This has been tested both 
in rodent and human models8. Initial studies established that a state of ketosis can be achieved and 
maintained in humans and rodents with various types of ketone/βHB supplements without the need 
for dietary changes5,9. Significant metabolic effects of βHB supplementation were demonstrated 
by a study in which βHB salts were administered orally to rats5. The rats experienced an improved 
plasma lipid profile as well as an overall decrease in adipocyte volume5. Interestingly, high-fat-
fed mice receiving a βHB-ester supplement displayed significant weight loss and an increase in 
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energy expenditure compared to high-fat and calorie-restricted mice10. In humans, 
supplementation of βHB salts resulted an overall increase in fat oxidation and a reduction in 
respiratory exchange ratio (RER), mimicking what is observed in individuals on a KD11. 
Even though several studies report that βHB supplementation can lead to alterations in 
substrate utilization and affect exercise performance, the molecular mechanisms responsible for 
the results described above remains unknown, although some hypotheses have been proposed. 
Once taken up by peripheral tissues, βHB is thought to affect cellular metabolism in two ways: a) 
by inhibiting class 1 histone deacetylases (HDACs), which regulate gene expression12,13, and b) 
through post translational protein modifications including acetylation, succinylation, and β-
Hydroxybutyrylation1,12. One of the most important peripheral tissues that utilize βHB is skeletal 
muscle, which accounts for up to ~40% of body weight in men and ~30% in women. Additionally, 
skeletal muscles are the primary site of insulin-stimulated glucose uptake and play a major role in 
the regulation of glucose and fat homeostasis in the body14,15. Therefore, any potential effect of 
βHB on muscle could be of great physiological and therapeutic relevance and worthy of further 
investigation.  
In this context, the research described in this thesis was designed to investigate the effects 
of βHB on skeletal muscle metabolism. To accomplish that, an in vitro model using L6 rat skeletal 
muscle myoblast cells were used. Using L6 myoblasts allowed for direct assessment of βHB on 
skeletal muscle without potential confounding systemic influences on skeletal muscle metabolism. 
Alterations to important components of glucose and fat metabolism specifically, were analyzed 
using various functional assays including: glucose uptake, glucose oxidation, glycogen synthesis, 
lactate production, and palmitate oxidation in myoblasts. Western blot analysis was used to assess 
alterations in signaling pathways related to glucose and fat metabolism. These included 
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phosphorylation protein kinase B (AKT), AMP-activated protein kinase (AMPK), glycogen 
synthase (GS), and glycogen synthase kinase 3 (GSK3), as well as content of carnitine palmitoyl 
transferase 1B (CPT1B). Using these data, the role of βHB in the regulation of skeletal muscle cell 
metabolism was evaluated.  
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Experimental Design & Methods  
 
Reagents  
 
Minimum essential medium (α-MEM) with and without phenol red, fetal Bovine Serum 
(FBS), trypsin, phosphate buffer saline (PBS) suitable for cell culture, and 1% (v/v) antibiotic 
antimycotic were obtained from Wisent Bioproducts (ST-BRUNO, Quebec, Canada). DL-β-
hydroxybutyric acid sodium salt (βHB) was from Sigma Aldrich (St. Louis, MO, USA). Protease 
(Complete Ultra Tablets) and phosphatase (PhosStop) inhibitors were from Roche Diagnostics 
GmbH (Mannheim, Germany). 2-deoxy-D-[H3] glucose (0.5 μCi/ml) was purchased from Perkin 
Elmer (Seer Green, United Kingdom). Cytochalasin B. D-[U-14C] glucose and [1-14C] palmitic 
acid were from GE Healthcare Radiochemicals (Quebec City, Quebec, Canada); and human 
insulin (Humulin) was from Eli Lilly (Indianapolis, Indiana, USA). Phosphate buffered saline 
(PBS) tablets were bought from Bioshop (Burlington, Ontario, Canada). Glycogen carrier. The 
lactate colorimetric assay kit was obtained from BioVision (San Francisco, CA, USA). Cell 
viability CellTiter-Glo® Luminescent Cell Viability Assay was purchased form Promega 
(Madison, WI, USA).  
Cell culture 
Stock rat L6 skeletal muscle cell cultures were obtained from the American Type Culture 
Collection and kept in a humidified atmosphere of 95% O2 and 5% CO2 at 37°C. Cells were grown 
in minimum essential medium (α-MEM) containing 10% (v/v) Fetal Bovine Serum (FBS) and 1% 
(v/v) antibiotic antimycotic referred to as growth medium. Cells were kept in 2 T75 standard flasks 
which were split at 70%-80% confluence. Each of the assays involved either a time course or a 
dose response treatment. Treatment began with cells being trypsinized and reseeded for the assay 
being run. Cells were given 24 hours to allow for surface attachment before changing the media to 
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remove any DMSO and beginning treatment with DL-β-hydroxybutyric acid sodium salt obtained 
from Sigma Aldrich. A 20mM stock solution of βHB was used to achieve the desired 
concentrations of 0.0 to 2.5mM (0, 0.5, 1.0, 1.5, 2.0, or 2.5mM) for the dose response treatment. 
This range was chosen because serum βHB concentrations typically range from approximately 
100uM to 1-3mM while on a sustained ketogenic diet7,112. An assay done with the dose response 
treatment would indicate which βHB concentrations are effective in eliciting some sort of 
functional change. Based on this, a single βHB concentration would be chosen for the time course 
treatment to determine the duration of time needed to elicit the response seen in previous assays. 
Cells will be treated for up to 5 days for the time course treatment, and exactly 5 days with the 
does response treatment. Growth medium was changed and treatment was readministered every 
other day.  
Glucose Uptake  
Cells were seeded into 24-well plates and divided between basal, insulin stimulated, and 
non-specific uptake conditions. On the day of the assay, cells were serum starved (α-MEM with 
antibiotic antimycotic only) for 4 hours. Wells assigned to the insulin condition were treated with 
insulin (100nM) for 30 minutes. Cells were washed twice with Hepes-buffered saline (HBS) 
solution (140mM NaCl, 20mM Hepes-Na, 2.5mM MgSO4, 1mM CaCl
2+, 5mM KCl, pH 7.4) at 
room temperature and aspirated dry. A specific glucose uptake solution of 10μM 2-deoxy-D-
glucose and labelled 2-deoxy-D-[H3] glucose (0.5μCi/mL) made in HBS solution was 
administered to all basal and insulin stimulated wells. Wells designated for non-specific uptake 
were prepared by using an uptake solution containing cytochalasin B (10μM). Cells were allowed 
to incubate for 5 minutes. The plates were then put on ice and washed twice with ice cold 0.9% 
saline solution in order to stop the reaction. Wells were aspirated to dryness. 250uL of 0.05N 
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NaOH solution was added to each well and put on to a shaker for 15 minutes to aid in cell lysis. 
200uL of the resulting lysate was put into scintillation vials filled with 2mL of scintillation fluid, 
for counting. The remaining 50uL of lysate was used for protein quantification via Bradford assay.  
Glycogen Synthesis  
After completing the time course treatment, on the day of the assay, cells were serum 
starved for 3 hours in starve media (FBS-free α-MEM containing antibiotic and antimycotic only). 
The starve media was aspirated and the control and insulin groups were treated with 500uL of test 
media containing non-labeled glucose (5.5mM) and [U-14C] d-glucose (0.2µCi/mL) made in starve 
media without and with insulin (100nM) respectively. The cells were allowed to incubate for 
another 2 hours after which 100uL of media was collected and stored in the -20oC for future 
experiments. The glycogen synthesis reaction was stopped by aspirating the test media, putting the 
plates on ice, and washing with ice cold PBS. Wells were treated with KOH (1M) and placed on a 
shaker for 30 minutes to aid in cell lysis. Lysates were transferred to eppendorf tubes and heated 
for 30 minutes at 65oC. 50μL of each sample was taken for protein measurement via Bradford 
assay. 100uL of glycogen carrier was added to each Eppendorf. Afterwards, 80uL of Saturated 
Na2SO4 and 1.2mL of cold ethanol was added to each. Subsequently, the tubes were vortexed and 
stored at -20oC overnight. Samples were then be centrifuged for 20 minutes at 5000-10000 rpm at 
room temperature after which a pellet was formed. The supernatant was discarded and the 
remaining pellet was dissolved in distilled water where 400uL was transferred to scintillation vials 
filled with 2mL of scintillation fluid for radioactivity counting113. 
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Palmitate Oxidation  
Cells were seeded into 35x10mm tissue culture dishes and subjected to a time course 
treatment. On the day of the assay, cells were serum starved with starve media (α-MEM with 
antibiotic antimycotic only) for 4 hours. The βHB treatments was added to each dish as the starve 
media did not contain βHB.  Starve media was then aspirated and 500uL of a solution containing 
non-labeled palmitate (20µM) and labeled (0.2 µCi/ml [1-14C] palmitic acid) in αMEM was added 
to each dish. Dishes were sealed using parafilm with a piece Whatman paper attached using tape, 
to the side of the film facing the inside of the dish. Cells were allowed to incubate for 1 hour. After 
1 hour of incubation, a syringe was used to pierce the parafilm and saturate the Whatman paper 
with 100µL of phenylethylamine-methanol (1:1) to capture the CO2 produced during the 
incubation period. Then using another syringe, 200µL of H2SO4 (4M) was added to the media. The 
holes created by the syringes were covered with pieces of tape to ensure there was no leakage of 
gasses from the dishes. One additional hour of incubation was given for 14CO2 collection. After 
incubation, the pieces of Whatman paper were separated from the parafilm in a way that ensures 
the paper does not touch the media. The piece of Whatman paper were then be placed in 
scintillation vials for radioactivity counting. Vials were filled with 5mL of scintillation fluid to 
ensure the piece of whatman paper were fully submerged. 
Glucose Oxidation 
Cells were seeded into 35x10mm tissue culture dishes and subjected to a time course 
treatment. On the day of the assay, cells were serum starved with starve media (αMEM with 
antibiotic antimycotic only) for 4 hours. The βHB treatments was added to each dish as the starve 
media did not contain βHB. Starve media was aspirated and 750uL of a solution containing labeled 
(0.1 µCi/mL [1-14C] glucose) in αMEM which on its own contains glucose at a concentration of 
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1ug/uL, was added to each dish. Dishes were sealed using parafilm with a piece Whatman paper 
attached using tape, to the side of the film facing the inside of the dish. Cells were allowed to 
incubate for 1 hour. After 1 hour of incubation, a syringe was used to pierce the parafilm and 
saturate the Whatman paper with 100µL of phenylethylamine-methanol (1:1) to capture the CO2 
produced during the incubation period. Then using another syringe, 200µL of H2SO4 (4M) was 
added to the media. The holes created by the syringes were covered with pieces of tape to ensure 
there was no leakage of gasses from the dishes. One additional hour of incubation was given for 
14CO2 collection. After incubation, the pieces of Whatman paper were separated from the parafilm 
in a way that ensures the paper does not touch the media. The piece of Whatman paper were then 
be placed in scintillation vials for radioactivity counting. Vials were filled with 5mL of scintillation 
fluid to ensure the piece of whatman paper were fully submerged. 
Lactate Production 
 Cells were seeded into 6-well plates and were subjected to a time course treatment. On the 
fourth day of the treatment, when cells designated for 1 day of treatment are given βHB, media in 
all the wells was changed. Instead of the usual growth being used, a version using a form of αMEM 
without phenol red was used. This created a colorless media which would not interfere with later 
steps in the Lactate colorimetric assay kit. Cells were treated with a 20mM βHB stock solution 
created using colorless growth medium as well. After the 5 days of the time course treatment was 
completed, 500uL sample was taken from each well, flash frozen and stored in a -80oC freezer 
until the next step of the assay. Once ready to conduct the assay, samples were deproteinized first. 
Samples were loaded into tubes containing removable 10 kda filters and were then centrifuged at 
13 000 rpm for 15 minutes at 4oC. The remaining sample at the bottom of the filter tubes were put 
into Eppendorf tubes. An initial assay was done to create a standard curve as well as determine the 
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optimal amount of sample needed for the assay, which was found to be 2.5uL. To prepare the 
standard curve, the lactate standard in the kit was diluted to 1nM/uL by adding 100uL of the 
100nM/uL lactate standard to 990uL of lactate assay buffer. After mixing well, 0, 2, 4, 6, 8, and 
10uL of the diluted lactate standard was added to a series of wells in duplicates in the same 96-
well plate. The volumes of the standards were adjusted to 50uL using the lactate assay buffer to 
generate 0, 2, 4, 6, 8, and 10nM/well concentrations of the lactate standard. 50uL of a reaction mix 
containing 46uL of lactate assay buffer, 2uL of lactate enzyme mix, and 2uL of probe, was added 
to all sample and standard wells. After adding the reaction mix, the plate was allowed to incubate 
at room temperature for 30 minutes in the dark. Absorbance of the plate was measured at 570 nm 
in a microplate reader. It was determined that 2.5uL was the optimal amount of sample to use for 
the assay. For the actual assay, 2.5uL of each sample was loaded into wells on a 96-well plate in 
duplicates. Volumes were adjusted to 50uL with lactate assay buffer and 50uL of reaction mix was 
added. the plate was allowed to incubate at room temperature for 30 minutes in the dark. 
Absorbance of the plate was measured at 570nm in a microplate reader. 
Cell Viability 
 Cells were seeded into a 96-well, opaque walled, clear bottom plate and subjected to a time 
course treatment. Cell viability was measured using the CellTiter-Glo® Luminescent Cell 
Viability Assay from Promega. This assay determines the number of viable cells in culture by 
lysing the cells to expose their contents to the assay substrate. Prior to the start of the assay, the 
assay buffer and assay substrate were thawed and allowed to equilibrate to room temperature. After 
equilibration, 10mL of the buffer was added to the substrate to fully reconstitute all the lyophilized 
enzyme/substrate mixture thereby creating the reaction mixture. The reaction mixture was gently 
mixed by vortexing and inverting to ensure a homogenous solution. At the start of the assay 
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standards were created by dissolving powdered ATP in growth medium to create a 100mM stock 
solution. From this stock solution, dilutions were created in order to obtain solutions with the 
concentrations 1, 0.5, 0.25, 0.1, and 0.01uM which would be used to create the standard curve. 
100uL of each standard solution was loaded into the same 96-well plate in duplicates. All sample 
wells in the 96-well plate were then aspirated. 50uL of the reaction mixture was added to all wells, 
standard and experimental. Blanks were prepared as well by adding the reaction mixture to empty 
wells to obtain a value for background luminescence. The plate was allowed to equilibrate at room 
temperature while on a shaker to induce cell lysis, for approximately 30 minutes. The plate was 
then taken off the shaker and allowed to sit for 10 minutes so that the luminescent signal may 
stabilize. The luminescence was then recorded on a microplate reader.   
Analysis of Proteins in Related Signaling Pathways using Western Blotting 
Cells were seeded into 6-well plates and underwent a dose response or time course 
treatment. Once treatment was completed, cells were washed twice with PBS to ensure the removal 
of all growth medium. Growth medium contains proteins and so and amount left in the wells could 
alter protein measurements. Cell lysis was induced using lysis buffer containing protease 
(Complete Ultra Tablets) and phosphatase (PhosStop) inhibitors. Once washing with PBS was 
complete and wells were aspirated dry, 100uL of the lysis buffer was added to each well. Lysate 
was scraped from the wells using a cell scraper and further broken down mechanically by using 
the syringe to repeatedly take up and then dispense the lysate. Sample lysates were collected in 
eppendorfs and stored in a -80oC freezer until next use. Once collected, an aliquot of the samples 
was used to measure protein by the Bradford method. Samples were diluted 1:1 (v/v) with 2X 
Laemmli sample buffer, heated to 95°C for 5 minutes, subjected to SDS-PAGE and transferred to 
PVDF membrane. Membranes were subsequently probed with primary antibodies (1:1,000 
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dilution), followed by horseradish peroxidase-conjugated anti-rabbit secondary antibody (dilution 
of 1:2,000). β-actin was used as a loading control. Blots were visualized using chemiluminescence 
(Luminata forte, Millipore, Billerica, MA) and scanned directly into an image quantification 
program. 
Statistical Analysis  
 
Results are expressed as means ± SEM and statistical significance was established at P < 
0.05. Statistical analysis was carried out using Graphpad Prism 8 software. For experiments 
where basal and insulin-stimulated conditions were examined, two-way ANOVA was performed. 
For experiments involving only basal conditions, one-way ANOVA was performed. Additional 
post hoc Tukey corrections for multiple comparisons were carried out where appropriate.  
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Results 
 
Glucose uptake assay following 5-day dose response treatment with βHB – Glucose uptake 
overall increased in both basal and insulin-stimulated conditions, reaching significance with 
treatment concentrations of 2.0 and 2.5mM βHB. Under basal conditions, treatment with 2.0 and 
2.5mM βHB resulted in an increase of 44% and 55%, respectively, compared to control, while 
under insulin stimulated conditions, treatment resulted in an increase of 26% and 42%, respectively 
(Fig. 1). An increase of 22% and 25% in basal and insulin-stimulated conditions was seen with 
0.5mM, although it was not significant due to the presence of many other concentrations in the 
statistical analysis. It’s been established that individuals on a KD can achieve serum βHB levels 
of 1-2.5mM and that the threshold for the effects of βHB on glucose and lipid metabolism appears 
to be at least 1mM111. In this context, a concentration of 1mM, representative of a less 
carbohydrate-restricted KD was examined in subsequent experiments.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1: Effects of different concentrations of βHB ranging from 0 to 2.5mM on glucose 
uptake of L6 muscle cells after 5 days of treatment. Two-way ANOVA, n =  8-9. * P < 0.05 
vs. 0mM Basal. + P < 0.05 vs. 0mM Insulin. # P < 0.05.  
# 
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Glucose uptake assay following 1mM time course treatment with βHB – Under basal 
conditions, glucose uptake increased significantly by 40% after a single day of treatment with 
βHB, compared to the control. After 5 days, there was a 60% increase in basal glucose uptake (Fig. 
2). Under insulin stimulation, glucose uptake also increased after a single day of treatment with 
βHB, however the effect did reach significance until 5 days of treatment with a 29% increase 
compared to control. Interestingly, the results showed a greater increase in glucose uptake under 
basal conditions compared to the insulin condition following treatment with βHB. This is shown 
by comparing the difference between basal and insulin-stimulated glucose uptake in controls and 
cells treated for 5 days. Under control conditions (0mM βHB), there is a 44% increase in glucose 
uptake with insulin stimulation, whereas after 5 days of treatment, there is only a 15% increase in 
glucose uptake following insulin stimulation. This suggests that βHB supplementation may have 
a greater effect on basal glucose compared to insulin stimulated glucose uptake.  
 
  
 
 
  
 
 
 
 
 
Figure 2: Glucose uptake of L6 muscle cells after 5-day time course treatment at 1mM 
of βHB. Two-way ANOVA, n = 8-9. * P < 0.05 vs. 0 days treated Basal. + P < 0.05 vs. 0 
days treated Insulin. # P < 0.05. 
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Glucose oxidation assay following 1mM time course treatment with βHB – 1mM βHB 
treatment was shown to increase basal and insulin stimulated glucose uptake (Fig. 3). Glucose 
oxidation was then analyzed to determine if βHB had any effects and if the increased glucose being 
taken up was being directed towards oxidation. As expected, glucose oxidation in L6 cells 
increased after a single day of treatment with 1mM βHB, reaching significance after 5 days with 
a 47% increase compared to control. These results support the idea that glucose oxidation is one 
of the pathways by which the increased glucose is being directed.    
 
 
  
 
 
 
  
 
 
  
Figure 3: Glucose oxidation in L6 muscle cells after 5-day time course treatment with 
1mM βHB. One-way ANOVA, n = 15-16. * P < 0.05 vs. 0 days.  
 
 
 
 
 
 
 
 
 
 
* 
52 
 
Glycogen Synthesis following 1mM time course treatment with βHB – Basal glycogen 
synthesis increased after 1 day of treatment, reaching significance with a 33% increase after 5 days 
of treatment with βHB compared to control (Fig. 4). Insulin stimulated glycogen synthesis 
increased by 11% and 19% after 1 and 5 days of treatment compared to untreated, insulin-
stimulated cells. This suggests that in addition to the increase in glucose oxidation, increased 
glucose taken up by cells following treatment with 1mM βHB may also be directed towards 
glycogen synthesis.  
 
 
 
 
 
 
  
 
 
 
 
Figure 4: Glycogen synthesis in L6 muscle cells after 5-day time course treatment with 
1mM βHB. Two-way ANOVA, n = 8. * P < 0.05 vs. 0 Days Basal. + P < 0.05 vs. 0 Days 
Insulin. # P < 0.05. 
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Lactate production following 1mM time course treatment with βHB – Treatment with 1mM 
βHB resulted in a 13%, 24% and 28% increase in lactate production following 1, 3 and 5 days of 
treatment, respectively (Fig. 5). Along with the increased glucose oxidation and glycogen 
synthesis, these results indicate that lactate production is another metabolic pathway that consumes 
the increased glucose being taken up by the cells following βHB treatment. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Lactate production of L6 muscle cells after 5-day time course treatment with 
1mM βHB. One-way ANOVA, n = 18. * P < 0.05 vs. 0 Days.  
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Palmitate oxidation following 1mM dose response treatment with βHB – L6 muscle cells were 
subjected to a 5-day dose response treatment with a range of βHB concentrations from 0.0 to 
2.0mM (Fig. 6). Given that literature has shown that fatty acid oxidation is enhanced when on a 
KD, it was expected that palmitate oxidation in L6 muscle cells would increase with βHB 
treatment. Contrary to what was expected, no significant change in palmitate oxidation was seen 
at any βHB concentration. These results indicate that the increased fatty acid oxidation seen when 
on a KD may be a product of the increased fat intake of the diet, and not an effect of βHB acting 
on muscle cell metabolism.  
 
 
  
 
 
 
 
 
 
 
 
Figure 6: Palmitate oxidation of L6 muscle cells after a dose response treatment at 1mM 
βHB. No significant differences were found between the various treatment conditions. 
One-way ANOVA, n = 19.  
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ATP cell viability assay following a time course treatment with 1mM βHB – The 1mM βHB 
treatment showed no signs of toxicity or negative effects on cell viability for any treatment duration 
when compared to the control (Fig. 7a). Unexpectedly, cell viability significantly increased 
following 1,3, and 5 days of treatment as shown by an increase in ATP concentration. Bradford 
assay indicated similar protein concentrations for all four conditions, which suggest that the βHB 
treatment may have increased cell turn over. Figure 7b shows the average protein content of the 
wells in each of the treatment durations. As can be seen, there is no significant difference between 
any of the treatment durations indicating that the βHB treatment did not alter protein content.  
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Figure 7a: Cell viability of L6 muscle cells after a time course treatment with 1mM βHB. 
One-way ANOVA, n = 18. * P < 0.05 vs. 0 Days. (B) 7b: Measure of total protein 
concentration in samples used for determination of ATP concentration. One-way ANOVA, 
n = 18.  
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Content and Phosphorylation of AMPK and AKT in L6 muscle cells following a time course 
treatment with 1mM βHB – Phosphorylation of AKT was significantly reduced by 1.4-fold, 1.6-
fold, and 1.7-fold following 1,3, and 5 days of treatment, respectively (Fig. 8b). This contradicts 
the findings in figure 2 that showed an increase in glucose uptake as the phosphorylation of AKT 
is required for the translocation of GLUT4 to the plasma membrane in order for glucose uptake to 
occur under insulin-stimulated conditions. However, there are alternative, insulin-independent 
pathways that may be activated following βHB. The phosphorylation of AMPK significantly 
increased by 2-fold, 2.4-fold, and 2.8-fold following 1, 3, and 5 days of βHB treatment respectively 
(Fig. 8a). This increase in the phosphorylation of AMPK indicates that the increase in glucose 
uptake may be occurring through insulin-independent pathways, which could explain the increase 
in glucose uptake in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 8a, b: Western blot analysis of the AMPK and AKT and their phosphorylation. 
One-way ANOVA, n = 6-8. * P < 0.05 vs. 0 Days.  
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Content and phosphorylation of GSK3 and GS in L6 muscle cells following a time course 
treatment with 1mM βHB -Phosphorylation of GSK3 was enhanced significantly 2.2-fold, and 
2.3-fold following 3 and 5 days of βHB treatment respectively (Fig. 9a). Based on this result, it 
was expected that the phosphorylation of GS would be reduced with βHB treatment. This is due 
to the phosphorylation of GSK3 leading to its inactivation making it unable to phosphorylate GS. 
This would allow GS to remain active and catalyze glycogen synthesis. However, there was no 
significant change in the phosphorylation of GS with any of the treatment durations (Fig. 9b). An 
increase in the phosphorylation of PGSK3 suggests that less GSK3 is active and available to 
phosphorylate and inactivate GS. These results may support the significant increase in glycogen 
synthesis shown in figure 4.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Western blot analysis of GSK3 and GS and their phosphorylation. One-way 
ANOVA, n = 6-8. * P < 0.05 vs. 0 Days.   
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+++ 
Content of CPT1B in L6 muscle cells following a time course treatment with 1mM βHB – 
Based on the results of figure 6 which showed that there was no change in palmitate oxidation 
with βHB treatment, it was expected that CPT1B content would remain unchanged as well. 
However, CPT1B content significantly increased 4.2-fold, 4.8-fold, and 6.6-fold after 1, 3, and 5 
days of βHB treatment.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Western blot analysis of CPT1B. One-way ANOVA, n = 6-8. * P < 0.05 vs. 0 
Days.  
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Discussion  
 
Herein, we provide evidence that βHB supplementation can alter the glucose and fat 
metabolism of L6 skeletal muscle cells. The glucose uptake assay was used initially to evaluate 
various concentrations of βHB representing ketogenic diets with varying levels of carbohydrate 
restriction. A concentration of 1mM representative of a less carbohydrate-restricted KD was 
examined in subsequent experiments. This is in agreement with previous work that found that the 
threshold for the effects of βHB on glucose and lipids appears to be at least 1mM111. On a 1mM 
βHB time course, basal and insulin-stimulated glucose uptake in L6 muscle cells increased 
significantly (Fig, 2).  
Though there is a lack of literature examining the metabolic effects of βHB 
supplementation on cell metabolism using in vitro models, our results are in agreement with results 
from studies using in-vivo models. One such study compared the effects of a ketogenic diet (4% 
of calories from carbohydrates) to a control diet (35% of calories from carbohydrates) on various 
physiological variables in obese men over a 4-week period114. Among the various improvements 
in health experienced by the KD-fed participants including a decrease in caloric intake, reduced 
hunger, and increased fat loss, including a decrease in blood glucose and insulin levels, and an 
overall improvement in the HOMA-IR by approximately 50%114. Another study by Mikkelsen et 
al., examined the effects of βHB infusion on skeletal muscle βHB utilization and metabolism in 
healthy human adult males115. Participants were subjected to low βHB infusion (4.7µM /kg/min) 
for 1 hour, medium infusion (9.4µM/kg/min) for the next hour, and high infusion (18.8µM/kg/min) 
for the final hour115. Samples of blood metabolites were taken before and during each of the 
infusion periods. Results showed that blood glucose and endogenous glucose production decreased 
as βHB infusion increase under basal and insulin-stimulated conditions115. Therefore, both our 
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research using an in vitro model and research using in vivo models shows an enhancement of 
glucose metabolism following treatment with βHB. Most human in-vivo studies propose various 
explanations for the observed decrease in basal blood glucose levels. This includes; the signaling 
actions of ketones (primarily βHB) in key tissues such as skeletal muscle, as well as an 
improvement in whole body glucose control/clearance with skeletal muscle playing a key114,115. 
Specifically, βHB treatment may altering skeletal muscle metabolism in a way that increases basal 
glucose uptake. These results were preserved with the stimulus of a meal which would be similar 
to our insulin stimulated conditions114,115. Another interesting finding was that the difference 
between basal and insulin mediated glucose uptake decreased with treatment. The 44% difference 
found in the controls diminished to only 15% after 5 days of treatment. It is clear that βHB is acting 
on signaling pathways involved in glucose uptake which are the PI3K-AKT and AMPK pathways, 
representing the insulin dependent and independent pathways respectively. However, βHB seems 
to be increasing insulin independent glucose uptake more than insulin dependent glucose uptake, 
as our results showed an enhanced phosphorylation of AMPK but not AKT with βHB treatment. 
As has been confirmed in other research, βHB treatment is not enhancing insulin-stimulated 
glucose uptake, but appears to be acting in an insulin-independent manner to increase glucose 
uptake111.  
To begin to understand the changes in the metabolic pathways responsible for the 
functional changes we observed, the content and phosphorylation of AKT and AMPK were 
measured. After a 1mM βHB time course treatment, L6 muscle cells displayed decreased 
phosphorylation of AKT, which is a part of the PI3K-AKT pathway (Fig. 8b). The mechanism 
behind this decrease has yet to be determined. This significant decrease in AKT phosphorylation 
would normally lead to a decrease in GLUT4 translocation to the plasma membrane and a 
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subsequent decrease in glucose uptake. This decrease however, seems to be compensated for by 
increase in the phosphorylation of AMPK, which plays a role in insulin independent glucose 
metabolism (Fig. 8a). In its active (phosphorylated) form, AMPK phosphorylates AS160, thereby 
deactivating it and allowing Rab to stay in its active GTP bound form. This allows GLUT4 
translocation to the plasma membrane and an increase in glucose uptake. Therefore, this significant 
increase in AMPK phosphorylation may explain the increase in glucose uptake we found (Fig. 2). 
Once it was established that glucose uptake increased significantly with βHB treatment, 
we wanted to determine what was the fate of the increased glucose within the cells. It is understood 
that glucose can be directed towards three main glucose utilization pathways; glucose oxidation, 
glycogen synthesis, and lactate production. We observed significant increases in glucose oxidation 
with βHB treatment suggesting that this is one of the metabolic pathways that glucose is being 
directed towards (Fig. 3). Although literature measuring glucose oxidation in similar experimental 
conditions could not be found, Cox et al., investigated metabolic changes in human male athletes 
pre, during, and post-exercise as a result of ketone supplementation110. While there was a decrease 
in plasma glucose concentrations and an increase in intramuscular glucose pre-exercise, muscle 
concentrations of the glycolytic intermediates, glyceraldehyde-3-phosphate, 2&3-
phosphoglycerate, and pyruvate, were significantly lower following KE consumption compared 
with high carbohydrate, and high fat diets110. This decrease was proportional to increases in 
intramuscular βHB concentrations110. These results along with the fact that participants ingested 
their beverage only 15 minutes before testing, after an overnight (12h) fast, suggests that ketone 
supplementation suppled skeletal muscle glycolysis110. This study highlights the fact that observed 
effects of ketone (βHB) supplementation is heavily dependent on carbohydrate availability, as well 
as duration of treatment with ketones. In this context, it is possible that participants that have 
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achieved ketosis for at least 24 hours, while on a normal diet may also experience increases in 
glucose oxidation similar to what we have shown.  
Glycogen synthesis was also examined as a potential fate of glucose, and we observed a 
significant increase in glycogen synthesis with 1mM βHB treatment under both basal and insulin-
stimulated conditions (Fig. 4). These results are in agreement with a study that determined whether 
a dietary ketone ester (βHB), combined with plentiful glucose, could increase post-exercise 
glycogen synthesis in human skeletal muscle116. Subjects given a ketone ester drink experienced 
50% greater muscle glycogen synthesis after 2h hyperglycemic clamp compared to controls on the 
clamp116. This difference was even greater when compared to controls given saline116. This study 
was very similar to our work considering that our cells also had a constant supply of glucose while 
supplemented with βHB. It is important to note that the difference between basal and insulin 
stimulated glycogen synthesis decreased from 54% to 33% with treatment, similar to what was 
seen in glucose uptake. This indicates that βHB signaling may play part in manipulating the 
signaling pathways involved in glycogen synthesis, and that it is also one of the pathways glucose 
may be directed towards.  
To further investigate the mechanism behind the increase in glycogen synthesis, the content 
and phosphorylation of GSK3 and GS were measured.  Cells treated with 1mM βHB displayed an 
enhancement in the phosphorylation of GSK3 (Fig. 9). The phosphorylation of GSK3 inactivates 
it, leaving it unable to phosphorylate and inactivate GS. Based on this, it was expected that PGS 
content would decrease. However, our results show that the phosphorylation of GS was unaffected 
by 1mM βHB treatment. While unphosphorylated, GS is in its active form and catalyzes glycogen 
synthesis. Together, an increase in the phosphorylation of GSK3 with no change in GS 
phosphorylation don’t explain the significant increase in glycogen synthesis we found earlier. It is 
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possible that glycogen synthesis may have increased simply due to an increase in available 
substrate/glucose as a result of the increase in glucose uptake.  
Finally, lactate production was measured and similarly to the previous glucose utilization 
pathways, it increased significantly in L6 muscle cells treated with 1mM βHB (Fig. 5). Although 
there is a lack of literature examining the effects of βHB on lactate concentrations using in vitro 
models, there is work that has examined the effects of a KD on aerobic performance and exercise 
metabolism in off-road cyclists117. However, results showed a decrease in plasma lactate 
concentrations in KD-fed participants at rest and during moderate intensity endurance exercise 
(between 50% and 70% VO2max)117. This is comparison to the same participants on a high 
carbohydrate diet (70% of calories from carbohydrates)117. A possible explanation is that the 
ability of the body to clear lactate from circulation through the Cori cycle may have increased117,118. 
This increase in efficiency may be due to the low-carbohydrate aspect of the KD making glucose 
cycling much more important. The Cori cycle refers to the metabolic pathway by which lactate is 
produced by anaerobic glycolysis in the muscles. Lactate leaves the muscle and is taken up by 
liver where it is converted back to glucose for further use by muscle117,118. In this context, the 
lactate produced by the L6 muscle cells would remain in the growth media after production as 
there would be no clearance mechanism. This is important because the assay used to analyze lactate 
production did so by measuring the lactate concentration in the growth media.  
In addition to changes in glucose metabolism, we also examined fatty acid metabolism 
following 1mM βHB treatment. Significant changes to fatty acid metabolism were expected with 
βHB treatment given previous research that has shown this. We began by measuring the effects of 
various concentrations of βHB on palmitate oxidation in a dose response treatment. Concentrations 
ranging from 0.5mM to 2.5mM, representing ketogenic diets with varying levels of carbohydrate 
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restriction, were chosen. We found that there was no significant change in palmitate oxidation at 
any βHB concentration (Fig. 6). Although an increase was expected, a possible reason for this 
result was that the high circulating concentrations of FFAs seen in humans and rodents on KDs, 
was not present in the cell culture media. There would also need to be a reduction in available 
glucose, which would help transition skeletal muscle from using glucose as a fuel, to relying on 
FFAs. Therefore, there wasn’t enough substrate available for β-oxidation to increase even if βHB 
was capable of altering fat metabolism. These concepts are explored by O’Malley et al., which 
examined the effects of βHB salt supplementation on cycling performance in healthy individuals11. 
They found that ketone salts were capable of altering metabolic response during exercise11. 
Specifically, the respiratory exchange ratio decreased at 30%, and 60% ventilatory threshold (VT) 
indicating a shift towards fatty acid oxidation during exercise11. They also found that total fat 
oxidized increased by 23% while total carbohydrates oxidized decreased by 8% after the 3 5-
minute cycling stages and time trial stage11. It is proposed that there would be a degree of glucose 
depletion as the subjects completed the cycling stages in a fasted state11. Therefore, it is possible 
that glucose depletion along with βHB signaling played a role in promoting lipid utilization during 
aerobic exercise. Our experimental design differs as the growth media for our L6 muscle cells had 
a physiological concentration of glucose, but a relatively limited amount of FFAs. Our results may 
have differed had we also experimented with varying levels of substrate provided to our cells. 
To confirm whether βHB treatment may have altered the content of proteins involved in 
fatty acid metabolism, we began by measuring CPT1B content, which is involved in fatty acid 
oxidation. CPT1B was chosen because it is responsible for catalyzing the rate limiting step in long 
chain fatty acid transport into the mitochondrial matrix for β-oxidation.  Although there was no 
change in palmitate oxidation, we expected βHB to alter CPT1B content in a way that would 
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accommodate a large influx of FFAs, which would be normally present in individuals on a KD. 
We found that CPT1B content significantly increased in L6 muscle cells treated with 1mM βHB 
(Fig. 10). An increase in CPT1B indicates that βHB may preparing the cell for a larger influx of 
FFAs. The importance of CPT1B is highlighted by Wicks et al., which created CPT1B knockout 
mice. Skeletal muscle fatty acid oxidation in these mice was 50% lower than controls, and similar 
to control mice treated with etomoxir, a nonselective whole-body CPT1 inhibitor119. Interestingly, 
the knockout mice displayed enhanced carbohydrate utilization signaled by lowered blood glucose 
levels, increased PDH activity and pyruvate oxidation119. The enhancement of CPT1B activity, 
although in the context of possible effects on skeletal muscle physiology, has been explored120. 
Henique et al., were able to express a mutant version of CPT1B, which was insensitive to malonyl-
CoA, its physiological inhibitor, in the tibialis anterior of mice. Results showed that fatty acid 
oxidation increased 40%, which mimic our idea that the increase in CPT1B we saw can lead to 
significant increases in fatty acid oxidation, given enough substrate120.  
To ensure that the 1mM βHB treatment was not having a negative effect on the viability of 
the L6 muscle cells, an ATP assay was used. The assay measured intracellular ATP concentrations 
as an indicator of cell health/viability (Fig. 7). Our results showed that there was no negative effect 
on cell viability. Interestingly however, there was a significant increase in ATP concentration with 
no difference in protein content between treatment conditions (Fig. 7). These results suggest that 
the βHB treatment may be increasing cell turnover, which would explain the increased ATP 
production. The exact mechanism behind these results is unclear, however it is possible that the 
increase in glucose oxidation we saw may play a role.  
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Conclusion 
 
The overall objective of this study was to determine if βHB supplementation can mimic 
the effects of a KD on skeletal muscle glucose and fat metabolism. Based on our finding it is clear 
that βHB does in fact alter glucose metabolism. We have shown that 1mM of βHB, which 
represents a less carbohydrate restrictive diet, significantly increased glucose uptake, as well as 
the utilization of glucose through glucose oxidation, glycogen synthesis, and lactate production. 
Interestingly, βHB treatment had no effect on palmitate oxidation, despite increasing the content 
of CPT1B. This suggests to us that given enough substrate, our L6 muscle cells may have displayed 
an increase in palmitate oxidation. Analysis of a few key proteins involved in glucose metabolism; 
AKT, AMPK, GSK3, and GS supported the outcomes of our functional assays. Our results suggest 
that the enhance glucose uptake is due to an enhancement of the insulin-independent glucose 
uptake pathway.  
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Figure 11: Outline of the effects of ΒHB supplementation on L6 muscle cell metabolism 
 
Our study showed that supplementing L6 muscle cells with 1mM βHB resulting in changes in 
metabolism. Specifically, we showed that glucose uptake increased significantly after a single day 
of treatment. To determine the fate of the increased glucose within the cells, assays to measure the 
three main pathways that glucose can enter; glycogen synthesis, lactate production, and glucose 
oxidation, were done. We found that each of these aspects of glucose metabolism increased 
significantly. This suggested that the increased glucose within the cell is directed towards all three 
pathways. Palmitate oxidation was measured to find any potential effects on fat metabolism. No 
significant change was found. The content of the protein CPT1B, responsible for the transport of 
long chain fatty acids into the mitochondria matrix, increased significantly. This suggested a 
possible priming effect that may be preparing the cell for large influx of free fatty acids. A cell 
viability assay was run to determine if βHB supplementation may be having negative effects on 
cell health. This was done by measuring ATP within cells which indicates viable cells. We found 
that ATP concentration increased with treatment possibly indicating increased cell turnover.  
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Future Directions  
 
In our study we observed that 1mM βHB is capable of altering skeletal muscle glucose 
metabolism, while changes in fat metabolism require further study. Although there was no change 
in palmitate oxidation with the dose response treatment, there was an increase in CPT1B content. 
CPT1B is the first component of the carnitine palmitoyl transferase system and is responsible for 
catalyzing the rate limiting step. It is also important to note that the cell culture growth media 
possess a fraction of the FFAs normally present in physiological conditions. In this context, the 
results suggest that the L6 muscle cells are capable of increased fatty acid oxidation if given 
adequate amounts of substrate. To confirm this, experiments in which L6 muscle cells are 
subjected to a dose response treatment using growth media with additional FFAs should be carried 
out. These experiments should be done with varying concentrations of FFAs that are representative 
of a range of physiological conditions. It is also important that the content of key proteins involved 
in the process of fatty acid oxidation also be measured. These include proteins in the carnitine 
palmitoyl transferase system as well as those responsible for transport into the cell such as fatty 
acid transport protein (FATP) 1, and 4, and CD36. These proteins are especially worthy of 
investigation as their behavior resembles that of GLUT4121,122. Both CD36 and GLUT4 are 
recruited from intracellular pools by the insulin-stimulated PI3K-AKT pathway121,122. Similarly, 
muscle contraction, and AMPK activation induce translocation of GLUT4, CD36, as well as 
FATP1 and 4121,122. These experiments would help to clarify if βHB concentrations representing 
KDs with varying levels of carbohydrate restriction can alter palmitate oxidation.   
When considering the possible mechanisms behind the βHB induced changes in the 
molecular pathways that caused the changes in glucose and fat metabolism we observed, the 
answer remains unclear. It has also been established that βHB is a HDAC inhibitor and is capable 
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of regulating post translational protein modifications such as acetylation, succinylation, and β-
hydroxybutyrylation. Through these interactions, βHB can alter the expression of various genes 
including those involved in glucose and fat metabolism. For example, PPARα, FGF21, PGC1α, 
and some FOXO genes such as FOXO3 are known to be regulated by βHB indirectly through 
HDACs 1 and 2. Experiments that measure the gene expression and content of proteins that may 
be subjected to these βHB interactions, using cells grown in media with and without additional 
FFAs, should be carried out.  
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APPENDICES   
 
Appendix A - Detailed Experimental Methods  
 
Lysis Buffer for Homogenization  
 
Reagent Concentration/MW 
NaCl 135mmol/L (MW=58.44) 
MgCl2 1mmol/L (MW=203.3) 
KCl 2.7mmol/L (MW=74.55) 
Tris (pH 8) 20mmol/L (MW=121.14) 
Triton 1%  
Glycerol 10%  
 
Prepare lysis buffer stock and store at -20°C. Aliquot desired volumes and add protease (cOmplete 
ULTRA Tablets) and phosphatase (PhoStop) inhibitors immediately prior to use.   
 
Laemmli Sample Buffer (2x) - (Bio-Rad, Cat#161-0737)  
Per 1mL: 950µl of 2x Laemmli sample buffer              
                        50Ul β-Mercaptoethanol  
 
Store at room temperature. Dilute the sample (1 in 2) with sample buffer and heat for 5min 
at 95°C.  
  
Preparation of Tissue Lysates  
  
1. Upon extraction, immediately snap freeze samples and store at -80°C.  
2. Weigh sample (~ 20mg for liver) and add to 350µl of lysis buffer containing both protease & 
phosphatase inhibitors. (Always keep samples on ice and avoid thawing while weighing tissue) 
3. Thoroughly homogenize the sample.  
4. Centrifuge the tissue lysate for 10min @ 12,000rpm (4°C).   
5. Extract the supernatant and transfer to a fresh micro tube.  
6. Take one aliquot for protein determination by Bradford method.   
7. Aliquot remaining lysate and store at -80°C.    
8. For western blot purposes, dilute lysates with 2x lammeli buffer (1 to 1 v/v) as needed and 
heat for 5 min at 95°C prior to use.   
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Western Blotting Buffers   
 
10x Electrophoresis/Running Buffer (pH - 8.3)  
30.34g  Tris base  
144g  Glycine  
10g  SDS  
Dissolve contents in 1L of ddH20 and store at room temperature.  
 
1x Running Buffer (pH- 8.3)  
10%  10x Running buffer  
90%  ddH20  
Mix solutions and store at room temperature.  
 
10x Transfer Buffer (pH- 8.3)  
30.3g  Tris base  
144g  Glycine  
Dissolve contents in 1L of ddH20  and store at room temperature.  
 
1x Transfer Buffer (pH- 8.3)  
10%    10x Transfer buffer  
20%    Methanol  
70%    ddH20   
Mix solutions and store at -20°C prior to use.  
 
10x Wash Buffer   
60.57g   Tris base  
87.66g   Sodium Chloride (NaCl)  
Dissolve contents in 1L of ddH20, store at room temperature.  
 
1x Wash Buffer  
10%     10x Wash buffer  
90%    ddH20   
Add 500Ul/L of Tween-20 and NP-40. Mix solutions and store at room temperature.  
 
Blocking Buffer  
3% BSA (w/v: 1.5g/50mL)   
Dissolve in 1x Wash buffer, store at 4°C.  
  
Antibody (Ab) Buffer  
1° Ab  – 1 part blocking buffer + 2 parts wash buffer + 0.02% NaAzide (stock in ddH20)  
2°Ab – 1 part blocking buffer + 2 parts wash buffer (NO NaAzide).   
Typically 1:1000-1:2000 dilution is appropriate for an Ab. This may vary depending on how good 
the signal is.   
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Resolving gel Tris Buffer (1.5M) (pH-8.8)  
90.86g/500mL of ddH20  
 
Stacking gel Tris Buffer (0.5M) (pH-6.8)  
30.3g/500mL of ddH20  
 
10% APS Solution  
10% (w/v) Ammoniumperoxide Sulfate in ddH20.  
Use 0.1g/mL Store at -20°C.  
  
10% SDS Solution  
10% (w/v) Sodium dodecylsulfate in ddH20  
Use 1g/10mL Store at room temperature.  
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Western Blotting  
 1. Take samples out of -80° freezer and place on ice.  
2. Place gels into cassettes, and add the cassette to tank ensuring red and black terminals of cassette 
correspond with red and black markings of tank respectively.  
3. Add 1x running buffer to fill the tank.  
4. Once samples have thawed, spin in centrifuge for a few seconds.   
5. Take out combs from gel and pipette 7ul Bio-Rad protein ladder.   
6. Add samples into each well according to Bradford values.  
7. Top up with running buffer to make sure tank is full.  
8. Ensure positive and negative electrodes are matched (black to black, red to red)  
9. Turn on the voltage for 60V for 30min, and then turn it up to 110V for ~1.5hrs until dye runs 
off the gel.  
10. While gel is running, can prepare 1x transfer buffer. Once transfer buffer is well mixed, cover 
with parafilm and place in the -20°C freezer until ready for transfer.  
 
Transferring the Gel onto a membrane  
 
1. Fill Pyrex dish with cold transfer buffer.  
2. Cut out equal sized membranes and dip in methanol to activate (2min). Also cut out equal 
sized filter papers and prepare the appropriate number of foam pads.  
3. Place membranes in transfer buffer after activation.  
4. Once dye has run off the gel, remove the gels from tank and soak in transfer buffer. 
Carefully remove glass plates. Cut off and discard combs of the gel. Loosen gel from the 
glass plate with scraper while keeping it emerged in the buffer.   
5. In the pyrex dish, place the black side of the cassette on the bottom, and place two foam 
pads followed by 3 filter papers on top. Ensure there are no bubbles.  
6. Carefully place gel on top of filter paper and use the roller to get any air bubbles out. Make 
sure gel is in the correct orientation so that the ladder will appear on the left side of the 
membrane when removed.  Note: transfer runs from negative (black) to positive (red). 
Always ensure proteins will run from gel to the membrane.   
7. Carefully place the membrane on top of the gel and roll out any bubbles.  
8. Place 3 more filter papers on top and roll out any bubbles.  
9. Add one foam pad and roll out any bubbles.   
10. Carefully close sandwich and place into transfer tank. Make sure black matches black and 
red matches red.  
11. Place ice pack in tank to keep buffer cold. Close the lid ensuring positive and negative 
electrodes are matched (black to black, red to red)  
12. Surround transfer tank with ice to keep cold.  12. Turn on transfer at 120V for 2.5 hours or 
at 60V overnight.   
13. Look for bubbles on ends of cassette to indicate successful transferring. 
14. Check on temperature throughout transfer time to ensure no overheating.    
 
  
 
Probing the membrane  
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1. Prepare containers to hold blocking buffer for each membrane, approx. 10mL per 
container.  
2. Once transfer has finished, open cassettes and quickly place membranes in containers with 
blocking buffer.  
3. Allow the membranes to surf in the blocking buffer for 1hr at room temperature on the 
orbital shaker.  
4. Pour out blocking buffer and add 1°Ab.   
5. Incubate overnight on shaker at 4°C. Ensure containers are fully sealed to avoid 
evaporation.  
6. The next day, remove 1°Ab and wash membranes 5x at 10min intervals with 10mL of 1x 
wash buffer to rid the membrane of any unbound Ab.  
7. Add 2° Ab and allow membranes to surf on orbital shaker for 1hr at room temperature.   
8. Remove 2°Ab and wash membranes 5x at 10min intervals with 10mL of 1x wash buffer to 
rid the membrane of any unbound 2°Ab.  
9. Membranes are ready for developing  
 
Developing the membrane  
 
1. For each membrane, use 3mL chemiluminescence (Millipore Immobilon Western 
Chemiluminescent HRP substrate) per membrane and incubate for 3 minutes.   
2. Dip membranes into ddH20 to rinse and place in radiography cassette.   
3. In the darkroom, expose film for desired time.  
4. Place film in developer for a few seconds until signal appears. Dip into water to stop the 
reaction, and place in fixer solution. Ensure ample fixing time.   
5. Rinse with water and allow drying. 
